var title_f40_36_41536="Patellar compression";
var content_f40_36_41536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patellar compression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patellar compression is performed to determine whether the patient's complaint of pain and crepitation can be reproduced by forcible compression of the patella against the femur. The patella is grasped firmly and moved back and forth and up and down in the groove of the femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41536=[""].join("\n");
var outline_f40_36_41536=null;
var title_f40_36_41537="Acute pancreatitis";
var content_f40_36_41537=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acute pancreatitis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/36/41537/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41537/contributors\" id=\"au6654\">",
"       Santhi Swaroop Vege, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/36/41537/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41537/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/36/41537/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41537/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/36/41537?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PANCREATITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Acute pancreatitis refers to inflammation of the pancreas, causing sudden and severe abdominal pain. The pancreas is an organ that lies in the back of the mid-abdomen (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"mobipreview.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ). It produces digestive juices and certain hormones, including insulin. Pancreatitis usually develops as a result of gallstones or moderate to heavy alcohol consumption over a period of years.",
"    </p>",
"    <p>",
"     Most attacks of acute pancreatitis do not lead to complications, and most people recover uneventfully with medical care. However, a small proportion of people have a more serious illness that requires intensive medical care. In all cases, it is essential to determine the underlying cause of acute pancreatitis and, if possible, to treat this condition to prevent a recurrence.",
"    </p>",
"    <p>",
"     This topic discusses acute or sudden onset pancreatitis. Chronic (long-term) pancreatitis is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=see_link\">",
"      \"Patient information: Chronic pancreatitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PANCREATITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     There are many possible underlying causes of acute pancreatitis, but 60 to 75 percent of all cases are caused by gallstones or alcohol abuse. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link\">",
"      \"Etiology of acute pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Gallstone pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because the gallbladder and pancreas share a drainage duct, gallstones that lodge in this duct can prevent the normal flow of pancreatic enzymes and trigger acute pancreatitis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"      \"Patient information: Gallstones (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Alcoholic pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol is a common cause of acute pancreatitis. Alcoholic pancreatitis is more common in individuals who have a long history of alcohol abuse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Drug-induced pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of drugs used to treat medical conditions can trigger acute pancreatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Post-ERCP",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure that is done to evaluate the gallbladder or pancreas. Acute pancreatitis develops in about 3 to 5 percent of people who undergo ERCP. Most cases of ERCP-induced pancreatitis are mild. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/63/28666?source=see_link\">",
"      \"Post-ERCP pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Hereditary conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acute pancreatitis can be caused by hereditary conditions, such as familial hypertriglyceridemia (high blood triglyceride levels) and hereditary pancreatitis. These conditions usually occur in children and young adults.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Unexplained",
"     </span>",
"     &nbsp;&mdash;&nbsp;No underlying cause can be identified in about 20 percent of people with acute pancreatitis. This condition is called idiopathic pancreatitis. Only a small proportion of this group will experience additional attacks over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PANCREATITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Acute pancreatitis frequently presents with sudden, constant pain in the upper part of the abdomen, although other medical conditions can also cause this type of pain. The pain may wrap around your upper body and involve the back in a band-like pattern. The pain typically lasts days and is often relieved by leaning forward. Some people have only slight abdominal tenderness and in 5 to 10 percent of people, there is no pain at all.",
"    </p>",
"    <p>",
"     In people with gallstone pancreatitis, gallbladder pain may occur before pancreatic pain. Gallbladder pain (referred to as biliary colic) occurs in the right upper abdomen, extending to the back and right shoulder. The pain gradually increases in intensity, is constant, and may be accompanied by nausea and vomiting. Gallbladder pain often follows a meal. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"      \"Patient information: Gallstones (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In people with alcoholic pancreatitis, the symptoms of acute pancreatitis often occur one to three days after an alcohol binge or after stopping drinking. Pain is accompanied by nausea and vomiting in most people. In severe cases, the initial symptom may be shock or coma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PANCREATITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Diagnosing acute pancreatitis can be difficult because the signs and symptoms of pancreatitis are similar to other medical conditions. The diagnosis is usually based upon a medical history, physical examination, and the results of diagnostic tests. Two of the following three are required to make a diagnosis: (1) typical abdominal pain; (2) threefold or more elevation of pancreatic enzyme values in the blood; and (3) inflammation of the gland on computed tomography (CT) scan or magnetic resonance imaging (MRI) scan. The number and type of tests is tailored to the severity of acute pancreatitis and the most likely underlying causes. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"      \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Once a diagnosis of acute pancreatitis is made, additional tests are needed to determine the underlying cause. This ensures that the correct treatment is given to prevent pancreatitis from recurring.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imaging tests provide information about the structure of the pancreas, the ducts that drain the pancreas and gallbladder, and the tissues surrounding the pancreas. Imaging tests may include an x-ray of the abdomen, chest, CT scan or MRI of the abdomen",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Endoscopic retrograde cholangiopancreatography (ERCP)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure that can be used to remove stones from the bile duct if your pancreatitis is due to gallstones or other problems with the bile or pancreatic ducts. In addition, ERCP can be used to treat some causes of pancreatitis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PANCREATITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goals of treatment of acute pancreatitis are to alleviate pancreatic inflammation and to correct the underlying cause. Treatment usually requires hospitalization for at least a few days. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"      \"Treatment of acute pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Mild pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mild pancreatitis usually resolves with simple supportive care, which entails monitoring, drugs to control pain, and intravenous fluids. You may not be allowed to eat anything during the first few days if you have nausea or vomiting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Moderate to severe pancreatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Moderate to severe pancreatitis requires more extensive monitoring and supportive care. This is because severe pancreatitis can lead to potentially life-threatening complications, including damage of the heart, lung, and kidneys. People with pancreatitis of this severity may be closely monitored in an intensive care unit.",
"    </p>",
"    <p>",
"     During this time you may be given one or more of the following treatments:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Intravenous fluids are given to help prevent dehydration.",
"      </li>",
"      <li>",
"       Most people with moderate to severe pancreatitis will not be able to eat in the early course of their illness. Instead, you may be fed through a tube placed through the nose or mouth into the small intestine.",
"       <br/>",
"       <br/>",
"       If you cannot tolerate tube feeding or cannot get enough nutrients with tube feeding, you may be given nutrition through an intravenous line placed in the upper chest. You can resume eating gradually once your pain resolves and bowel function returns to normal.",
"      </li>",
"      <li>",
"       About 30 percent of people with severe acute pancreatitis develop an infection in the damaged pancreatic tissue. Antibiotics can prevent infections and control infections that are already present.",
"      </li>",
"      <li>",
"       Acute pancreatitis is sometimes complicated by extensive damage",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       infection to the pancreatic tissue. In these cases, the damaged",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       infected tissue may be removed in a procedure referred to as a necrosectomy. Necrosectomy can be done as a minimally invasive procedure.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Gallstone pancreatitis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people who have gallstone pancreatitis, the treatment of pancreatitis is usually coupled with the treatment of gallstones. This may include a procedure to relieve the blockage caused by the gallstone(s).",
"    </p>",
"    <p>",
"     Gallstone pancreatitis recurs in 30 to 50 percent of people after an initial attack of pancreatitis. Surgical removal of the gallbladder (cholecystectomy) is often recommended during the same admission in mild cases to prevent a recurrence. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"      \"Patient information: Gallstones (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In people who are elderly and who have serious medical problems, it may not be safe to remove the gallbladder. In this case, ERCP can be done to enlarge the bile duct opening. This would allow stones from the gallbladder to pass, helping to prevent a recurrence of acute pancreatitis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804510769\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027416\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/26/42401?source=see_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=see_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027442\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=see_link\">",
"      Patient information: Chronic pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44774?source=see_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/63/28666?source=see_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44504?source=see_link\">",
"      Predicting the severity of acute pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/001144.htm\">",
"        www.nlm.nih.gov/medlineplus/ency/article/001144.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/pancreatitis/\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/pancreatitis/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Gastroenterological Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/pancreatitis\">",
"        file://www.gastro.org/patient-center/digestive-conditions/pancreatitis",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/36/41537/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/36/41537?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41537/abstract/1\">",
"      Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41537/abstract/2\">",
"      Kingsnorth A, O'Reilly D. Acute pancreatitis. BMJ 2006; 332:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41537/abstract/3\">",
"      Heinrich S, Sch&auml;fer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006; 243:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41537/abstract/4\">",
"      Swaroop VS, Chari ST, Clain JE. Severe acute pancreatitis. JAMA 2004; 291:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41537/abstract/5\">",
"      Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc 2005; 61:363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_36_41537=[""].join("\n");
var outline_f40_36_41537=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PANCREATITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PANCREATITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PANCREATITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PANCREATITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PANCREATITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/2/12325\" title=\"figure 1\">",
"           Pancreas anatomy",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41538="Classic achalasia Ba swallow";
var content_f40_36_41538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54252%7EGAST%2F53672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54252%7EGAST%2F53672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 395px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGLAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Z8PWK6ZoVhZICohhVMH1xz+taFFFAAQDnIHPBoAwMDpRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeN/HrwXZXukyatDHtuhwwUdeOteyVjeL4o5vD14koByhAOOlAHwJqg8mN0Oc5A545rmXwGOM/TGMc12fjaNI9SuI4pA2xjnnHGev61xwHlykSgFs5yTxQAkAzKAFDeoNWrslIlVRx3/AAp0UsZ2gfePIGOlM1JizKScg+vX86AKJGcckVFMny5AjwMff6USSqVLJhivvwD0prvsCKTuYY554NAFORNhIzkgkYxTSMHB61M6oJ3Dl9uevv8A5zUJAycHP9aAEooooAKKKKACiiigAooooAKKKKACiiigD9VKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfGUgh8NX0jEALGTz3rarhvjJqqaZ4Hvs5Mki7QB6UAfEPii7abVbt8KDvxx2561zscjohCsQvfHrVrVi/2lyzZDE8A+9UaALKRyl/4gDyTyOtJczM5KjKqMfKetLDO4H3SQMZ9gKq3LFiz79o6k4oAVvmOe+c9KgmUNnBwd2D+Ix/Wq0kkgALEhjyDntj8qi3N/ePTHXt6UAKxcbgWPB5Ge9DA8FlIB6U3PGO1JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+qlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfOn7THiH7RcW+j2jANFzJ83JNfQt9OLaznnY4EaFs/QV8TeNtQfV/FF5dvIzDzCAT3HY0Aeb61AdwlAzn09KyTXT6hGZ42yCX5+7j8a5xhhiHYZTj1zQA3ACnPJx+v/AOqq87AKwBGTwenXHerKruzkHPByOmPWqV0VDkleSPoCaAKpORgZx3yfSmn04OPSpZkVdrKCFbPynqMVDQAUUvGPekoAKKKKACiiigAooooAKKKKACiiigAooooA/VSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ+MOuRaD4Ev7mTO518tADjkivjFr55d8pUfOdwPua9j/ao8UtcahFoEMp8mIBpExwWrwGKcgBAzbh0Awc0Aa5hBtAw5PUjsa5W+h/fEpz1J59K6zTX8x+VbJHAPBHPSqGs6euPkAU89R3oA5pRkAsMLnrjtUMwQFm4Ckbcn0q2kaFArFlfnIPas6/cfcGQOo9/rQBXnCHDIV57D/PFRce9JRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfqpRVTSL1NS0qzvY8bLmFJlx6MoP8AWrdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/wDGT4u23hN5dI0wGbVmXBYHiIn+tewV8zftAeApLfULnXrRXMUrbn44B69aAPDNX1C51S7udRvHeSec5LHOd2ef6VkQx7ZSzK5ZemBnFXrmbZF8u3PQGqRmLNlcjB7NQBuaVcsTEHUADn+tXdXVJUYqwA25yPWsaKQ/fzjaepGOR3onuwWxJ8uAcADsKAMq7DQRMTjOOCD+tctNjzXKnIJzmuqvDvjkYlSMHAH88VykxzK5IxyaAGUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6H/ALP2uLr3wm0GfOZIIfs0n+8nH8sV6LXy/wDsVeJlk0/WfDc0g3xOLuBSex4bH6GvqCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L43uifDrUd4BzjAPr1rva8i/aQ1a1tPCC2Ukw8+duIgeSvrQB8Yz75iRIGxnjaetP0+3BOXkPA556CtttH8yHK7Rj72e2e3vUY0mWJV8rqTwQKAIBJiNBCrEd8DOB/jUMsrbVYkCQ+nHy4q79kkiHIPLZ+Xp9MCoZyY35ACMuDkYz+IoAzLkqsBy3JBFczIEU4UkkdeMc1v6pLySTnHJxiudPX0oASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA9F/Z/8Rp4Y+Kmi3dxI0dtLJ9mlIPGH+Xn86/Q+vytjdo5FdCVdSCCOoNfol8C/GEfjT4c6ZfeZvu4EFtcg9fMQAZP1GDQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV88ftLaBNdarZ6g+42wj28DIBBr6HrnfH+nRal4WvY5kViiFlJ7H2oA+N4YIvJX5cggdaglu/Jl2AjHOM1dLoJZkXaAjHvz71m6hFHJIAMAY4K8daAGXT/ahkqm4NnIHFYmsuHkAAO5ePwrQ1CZoIcoQODWDNIZptzHgnH4UAZGpBtzbSAxHBxisu4RVCkdejAcc1r6g4D8AFgOg6k1hszMcsST0oAbRRRQAUUUUAFFFFABRRTkUswA70ANpwUkZ7e9TSW5UrkgZ6knjNK8bIgVNrA8nAB/z3oAr4/SkpeQO4B/Wg+1ACUUUUAFFFFABXun7KHj1PDHjR9H1G48vTNWAQFj8qTD7p/HkfjXhdPjdopEkjYq6EMrA4II6GgD9UaK83+AHjRvG3w4sLu5cNqFqPs1zzkll4DH6j+tekUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn8T9Yi0bwheyzMo8xSg3H1rrK+R/jn4p1XxJrj2tvbzx2Fs5UBshWxQB59a3Yaec5YhmJO45yDSygOvOdrdR0FVrONkJeRdr9NuOlaaIs867mB+UEkDr9aAMHUm3gxgkqO3XmsK43xgfI2T145Arr5rVPMkbZwTjr79ayby2Tz+QeOn0oA46+EjsQu7KnOSeeOMcd6qpaM2CWAH45rZ1GNUuDg+o/KqgAHSgCjLbiNMlvxJ4qGRQrYU5XGQfWr1wispZsEgHAOapS5ODgAdAfXFAEdFFFABTlUsQB9KfHC7EZVgp74q7HGFUAonXPHagCtHbFkbfuVu3SrKIkeGC4AH3jUn8Q5/CmNvLYxlSR+XegBJgp5O0lezdB71UkkUlioGCOnIx2qabYNzFSWbjrjFVgg/vAg/5yfQUAOELGIOvPBJ9sVEATnAJxzVgKsYIZgwLYxzzikIJ3tF9xuPU9M0AV6Ke4wTwRjg/Wmng0AJRTs/KB2FFADaKKKAPdP2UPHieGPGj6PfyFbDV9sYJPEco+6fx6V9wV+WFrPJa3MU8DlJYmDow7EHINfoD8BfiVb/ABC8JxmZ1XWrJVjvIyeWOOJB7H+dAHp1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZd/oGl37Frqyhdj1O0ZNalFAHi/xJ+EtjPZTX2jqYnjUuYx/+rmvntUktbueGQfOmQV6ZIr7rIDAhgCDwQe9fHfxF09LDxxfoMLmQlVA470AcU2Vm2MMHH19KoXufP6DBFa16Ntxnn5gPwqtJEJBuK528k4/SgDmNVCAhWyAwAGPWsWt3VwVkbarjbwOM5OawjyaAGyBShD4298nFZrcA7hz9MYOatXMjAlWChR6Hkg8VT7UAJU9tGzPnbwMcntT7aDLEyA/L2IrRhh3n5QQOmQKAGIpOAAeeBmn7cbhwCODnn8P51ehiCKTtI5z1zjimzBmkXKttU5BUjr9KAKOM5/vdcYptWJo3VQVQqp4IBzUSJubAzjtkdaAIJIlkyT97GAc9KR40OWYEbRjI7d+KuJGvf74ONjcbvT6UGBsZZcE8ADuaAKfkjaqtlgM5yfXvSEOrghFxwvB6Dv+FTHg0gAAwPrQBUSInIQFVzhgcZ/+vx/Oo7pNpGCCB8o9R3/rWh360woCxYqCcY69qAM+SMoo3Fck8Adx60VPeqFxgY3Hn3/zmigCpRRRQAVv+CPFeqeDPENtq+iztFcQsNy5+WRe6sO4NYFFAH6SfC/x7pnxA8Nw6lp0ircBQLm2z80L9x9PQ12Ffmj4A8a6x4G1+HVNEuGjZWHmxE/JKueVYd8199/Cz4haT8Q/Dyajpb+XcIAtzasfnhf09x6GgDs6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbLIkUTySMFjQFmY9AB1NfGvxE1qPXPGl5d2hHkeaURscHmvf/AI33962hf2TpTt51zxIE67a8DXwRqlk4aaBlUDngk/yoA5rXAYLASMF56ZrEs7liybyWD44JrtPFGmyC1KOhwFydw/HpXCsGWUrnGONw7H/P8qAItejSRsYbIHJHb/PFc06FWJCgqpwSM4NbetSHysBs5zndWEXYrtLHH1oAo3akljgnpzjp7frSwwtkMyqRk8EDp/ntUssW91IY+4z1FTW0B4jQ5PUk0AWrS32jcVIbqCefzq/AgTptJGThjnsTRbXMYVI5VUlRnGPu57VbUxbVKYVhkqGOKAK08YRhgHkc+mfaoWG5SMD8RkVpTDeyIRk9TwcEd6rz2+0gx5IJx9DQBR2YG3AcDru65qMQDJHI4wFPf8fT2q1sKkjGD3zS44GAc9aAIgqvkkMMqRyOeac6llPQqcA07aWYAZz6etIenHWgCusQOVwDt/76HpzVWaPy246HpnqK0xgg81BLEsr4IAxzkdT9aAM+kHyg5Pqcmp54yrHnJ4yO/TrURGCR1x3FAFG5GGDx5O4dcH0/w/lRU8se9hz3HUZooAzqKKKACiiigArqvhz431XwH4ih1XSJMEfLLEfuyp3UiuVooA/Sf4a+PNJ8feH49R0mZTIABPAT80TehHp6Gutr82/hh421bwN4lh1HSJGKk4mgJ+WVfQivvX4d+PtJ8b6Yk9i/lXYX97aycOh749R70AdfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU5tNtZ7sXMsQeUDAJ7VLJZ20kZR4Iih6jaKnooA4Xxj4CstUtJDYwpHIVIKAcH3FfKXjnwpeaNqUkUtuQNxwWGRX3PXN+MvCdl4msylwiidR8r4/Q0Afn3q+8IqlmbGMnGKyEJI+bbnPY16X8WfC0nh7W57eJeOc54NeaIixjCLj6UASohdioGT9au2tuUbI3Fj0GKZayl2YYwvUD09q0YE3Y2jBxwc45z/hQBXZCrtwAeh4px+UoylgevIqw4EchLbgSTk4GD9Pbmo1kVFOFyw6MR0oAeLr+8isSMHt+FKUlYB42YqRxz056VCAWfkZLH1xU1uJE8wYJK4+X/AD/KgCBAVccAt1AIzmpGUiQJINoZtx5yRVtDHNuKgZ6Zxz9aJYiUwcbxwTjnHpQBSUbC/wA2GX07npTWjIJ25ZRnke1WRG06Z3YUdFGCOn1qSGEpj5R2Jzz+VAFNFLK+1d2BnPTFRkD8qtzRMzkkgjO3PPA65omjGF2gM33AB0FAFFokIClcjqcnnP8Ak1BNARkxgDsQOc/561pNGm75vMB4yCO+fWnFd8bmZsdxxg+nI/L86AOfdeoP6H/Cir9zbbmLKOSOMDGfeigDnREW+4VY+gqRbaQk5wPrU1kwKkAAEdcD9c1aHPGOT0oAyWG1iD1BxTa0poA7ZbIPQ8f55qnOix4Ufe5z/SgCGilIwcHrSUAXNKlEN2rEA+1dvHrmo6eI7nSrmS0nU5VonwRjtXn0bbXVskYPat2xvg0eHGF7EjpQB9GfC79oq5tmh0/xqrXEf3RdqPnX/e9f519IeGvE+jeJrXz9E1CC7TGWCN8y/Uda/O6GIySlkw+c8gfh/k1o6Rf3+nXsdxpl5PaTIch4n20AfozRXzJ4A+NutWNvFbeIYxqaf89vuyBfc9/xr3Pwv478P+I40FjqEK3LDm3kYK4Ppg9fwoA6iiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+V/2nrVI/FKyANl4gQDwGJ64r5xmQJclSOM9Mf0r6v/ap00/8S7UmOI1Qx569Of618tXDhpx+7V2bJ5GD3oAfCu1VLj5sDdjqavWYBWTG76A/1qoExGCB8o461ZiG4sEAUg4ypPQ/5/lQAjQhNm8tjIznoOMmojE4LDaeBk/Sr7x7lwGIHuM/zpDGu0567cF/UUAUkQuvDgAcHPAFSxu4JQNlBzlR/L8eKmRtrhCMsBlunH4VIIl2rt+UA5AHH50AVjmJQ8YIY/eX1HPJHapknG0mTgZ4I5GKndWC8qRkcZ4zVaSMlCSMeiryD/k0ATlFL5UFcdOfzoAKkhsDsB3qJMJkLnCkBgF6n1/z6Vet3R4iJSAo6cc85oAhVSxwvJ9KiWPazMMknjJ5x7VZni2DKncnqO1RHjggg96AGIAny565I/z+NV5cZDRKSRjhfTH6cfyq0T14NNI2qWJwCc5PSgCjcRney8sBwBjtRUokMqkSYXnBzkYHH60UActaKBHyvOevr3Bq0o2P84OAcHnFRgEcHp2pxxgY/GgCSWQOFIAGBjb2+oqI8irbp/o/3VbaOCOo+tVygxlTkAcn3oAoT26pj72AOuP51BJEyMVPJAzxWnUc0SyLggZ7HHSgDPRd2csAPc1et0Kljng9AOn1psdqAwxkt2+tbVpYhmXdgnv3A/CgCTRkcHLIdp5Dfh/n866GC1HDZH3skAdaigs2WMIF29wx7/WrtrCIvvnJJ5x6UAa1qgSABSOe61mymRJBJbSMsmchwcEfWtDzQsR8shgijrVSZ97bjjd3x0oA7fwh8X/EvhgpBPM2pWKkZW4ySB6K3UdfWvo/4f8Aj7SPGtl5mnv5dyoy9u5G4e49RXxg0bGTr8nUgnOauaRqd9oeoR32mXEkMyMCNrYHHr6UAfeVFeQfDT4x2OtW8dp4iZLO/AAEvRJOP5163BNFcRLLBIkkbDIZDkH8aAJKKKKACiikJCjJIA9TQAtFZ11rFlaqTLKMexFY9x450aHlpxt7EkCgDqaKyNP8SaVfnFveRlvQnmtcHIyOlABRSEhRkkAeppFdWOFZSfY0AOophljXq6jtyap3WrWVvGzNcxZHH3qAOD+Ommxat4Z8j5vOXLKF5/SvjK/0iW1vJt4JK5yeuPavsHx34utPLkXKuMYYCvnzxJdadN5zpHhie+OKAPNwhbHA7AduSOKvQJsjUbcHvUk6RvOJETH+NN2hQQg+8ck+lAD+1MYAkAjPU+3+eaVsdduSAcGkyePlPPrjigCWG1Yg7ECjr0xmrDWEgi8wDcRnoO1WdNuoQ6i5GQOueBivS/BdhpWtXCWvnRwKcD5+cmgDyJlZfvKRn1FMYgMBkZPSvpvxN8D47my8zTJ1kl2k7ccHjtXzh4p0W90O+MN9E0bxscZHX/OKAKDxbmDA87gcE8VLxj3qvDPvK7htz69D9KlDKwDA8djnrQBIJAQVZiep4Pf/ADig4AwMk+tNoHIoAU0HkAE5A5HtT1BQrvXcDyFz+tMbAY4OR60AVbhNyk9MKTtJ/XiipJHGWCg+ZtyOPrRQBzJRwoYqdvXOKfCCu5trcDaCOxqxboPLYBQykjB9akdWTaY+FGcjtQA2WPeMBF+Q8DPUf0pqKImaPBZCMH1/zipoifKDMR0z9KJEDDHAJPB98daAM912SYBzj1GP0p9vEZC3BxggHtmn4HnfPywA6E8np/k1cQbVA9OntQAkMSoAq/ie9dBp9llldFK4wcbcms2xVpHCjJAOcHke39a6y0UWqBTgbsYXPQc9aAHwQ4XbIgOec+ntVe4j8uQgLhT05rRYZ+7wcYB64pHUI5bZ844OOtAFWG2GD5mCT6HkVCYn8xkC7io/SrxBVyUUHd15/Kj5vMBKA8dQefp70AZwRznCnjg+1Hlk7QQMP09K0JmKRM3Tp26VSuTmTht3GTyDzQBNDaKVG8lTkgADoK6nQvEfiTQoFOi6pMkZbcY2YsD+BrmNPZmYoct0xnp9K34o0VW3ZLkAHPOaAPR9A+NGvwjGr2NvdKP4kGxv04rZuvjoVjPk6C4fOMvNx/KvLbBY0uVQseRj5RkfhVbX5Ht7kINgXse/0oA9DufjjrcxaO20m1gJOFcksf51y2ufE7xdqQdHvkt0P8ESbf8A9VcasjZZmVdx61GXDk5YN05Jz9KANSTWNXvFYT3s0oPBwcdaoGaZiS8jkn1NJBlufmVScMenGabIAW+TO3PfrQBc07ULmzuo5YZmVge54r2Lwd4/dtkdxejKjnJ/zivEwm8HlcYyc1Zs41UqY3K7f4Qefz70AfVllq41QlrN9wXkgkZqwIbuSMtHvLHoK+ZrPV7+0jP2O9eHnIA5HNX7n4g+IUCRLfOEjHYY57UAes+KLy7skkW6uDG3UAnGO39K8a8SeIp5LmSNbpgQMHa36/SqF1qt7qExa/ummdudmc89axLgK4cAYUjjjOKAMnWL68ml+adyhYjkkf5//XWcJJCrKz8dw3Jpb3aZcKSSOvNOVMINyhh97OMde2aAInbdtKrwgAPFLDs8zDYCn+9z/n61FyegzSKwbO05wcGgDc13QbnQtTFtqIVNyJNC6/NHPEwyro38Skd/z5yKz50QKxQdSAPT8Pyr6S8MeG9P+KfwT0iC6lSPVNMR7WC6A/1LJwqt6qU8vI/Edq+br2A6feS2ztHJNA7IzRSh4yQSCVYcEe4NAFMxO74jB3HhuccVZ0q4uLO4WSKbaqkc9DUTzSeZu+Xd069PpVa5uJSEJA5GACPm/wA9KAPpT4cfEqa3hto7+XzYGwuSc+3T8a9K8beA9H8cacss0YjuHUMky/1r5f8AhPGuqanFbMVEmQV3nr/k19j6Epi06KB2UvGNp20AfG/xH+GV94MuldkaS3bpIoyD9MdK4HzVZlUq27PIx0r9Btc0iz1uwez1CJZIm9eoPqK+d/iF8C9QLeZ4eVJgzdF4KigDwPzQGCsMMTjr/n0qaJfMfauTzgkDpXvfhj9nR3tA+tXqwysudqruIJ7Gunl+FWmeGNEOY1u2z/rMYK0AfMwZreTy5Pujpxn8aFcFGcKuMY2qADj1NejeKvBsMrmeyfag5YYxmvNdRjk09njPOSBwevt+tAEC4fBXDdwRzRSeYC27hgCdxJooAyEIZQ44z6jmkXdubg7eMZ4+uKceBQpYDk884+lAAaWnONvynGQM8c5pWTa4Xadw6gnvQBCFCjCgYGSB71KrZA2qC3Y4/pSMMHFSWykzgA4I7jmgDc0y2SKIMBhmHPOcVvQxkFSRmQ8E1m2kB2RLjbuGc/zrp9NjRIoxIuFB4OOcetAEDWzBV2rlh1Pr09fxqF43YlsEgknPTPfNb7z2+0KV+UkZ4xiofILKGi3HIGc/rQBlpayMAQUIPPehbfkqzbW9MZyPWtGK2MavlSqjJJPc06KBpAWAHGRnNAGDOoMWxl2qBg4HSqGIzlgDsUjqeTWrcpidgcY7jrms+7UIqqseAON1AC2iNuLMmOeCf14ranuDa2oZiCeh9/8AJxVCEbmGT1wMk8fWl10HyY0Tjbg568UAWLXUfMeM/Kp3AnIOPpVzXSC6uW5x19vWubsx+8A3Hpn8j/n860rxmFsSQWIGDk9f8evWgCkjB7oEPuz7Yx7VPGihUCg4XoSKzcknGCSx61dG9JIgzHaSRyfyz70ATRqyg723Enj2qRlK43DGRkUxORuwwz2NONAEtum7liMD+HP3j6UmwyAskZxnsc1ciiKomSQVycZ4zV+ztHlKkDeO4JIoAyW8wLtcMwGMr6/j9TRPFmRWUHDDJB6iuhm03yiN/TocHvUc9mrKdow2fwBz3oAxxDsnDLhUUVzuuXeGaODIBJ9ga2dWumhJiRsPjBGK5K6kMkgLZ3AYb60ANhBD+YcseTkj0GRzUskrOnTaqgcep+npREMwjL5AP3cfy9+aaY8AAqwdmxkjAoAiZi33iSfUmkXAYZGR6Uh6elAGKAO8+GHjjUvBmrWT+dKdF+0eZc2yNw6soVmx3IABA9QPervxs8Jr4Z8RNd6bGh0PVv8ASrSRPujOGZB7DPHsRXBxO3kxctuzwOOQOMV7R4EeP4h/DS/8FX0gl1fSlN1pkhb5mAzhOfQnb16MOPloA8LAzk88Cqt2pZAfL+buc9K1L4PbXM0ciyJMh2srZDIR1BH9KoSkmIkDjHcf0oAh0vU7rTLqOayJWVXBBBxj/PFfW3wg8aC7sIBfzEyGP5ia+Q2QOpkwB3wBjI/yK1dN8Q39go8id4uNoKn/ADzQB+g9vPHcQrLC4dG6EGpK8s+E/ieMfDVL+aV55IuCp7n6+9d/4a1ddb0uO8ERiLEgoT0oA1KbLGksbRyqrowwVYZBp1FAHyl8a4bywu79rdjCqTHAB4wK8RmvJp8u7fOMfNn9K96/aRnuf7amV7djCRjheCB0NfPsSqzgMSBgk0AP82WRCo7fMT3opQgMqqpJJHBz+v5UUAQhSxY7s4GefTpU5iVH8uTgHo+cYp9tGNnJLHnKr2//AF4qaKPYSVJwxzjpigCssfKgbiOo7HIPIHp1/Sn7Du2SZB/hfjJ6VIEJQhDuPIbcx/XHWp4ovKhQEYyMgE0AUfJfGwp1Pyn0/KrKxgElgAd2cgnn0q8YUaENGSzDg7R3qCaLy5AMtgcjnqPegDoNHO+MAltuR8x4rfciGDIBwO2ayPDqD7GwlCkA5yT0rWn2yW5wRgc5HOaAK5lErlY0wW4LHritO1d1dEGdnp2xWNbjzJgiAt8w+v8AnmuijgVIwGG5s5yKALE4MiH7o3DHA6VnO0lrFIQ3I7Y9uv6VctneZJM7VAPTvx/+usuaTy2US7gTxk9qAMDUHZm3HjOeQf0xUabZUADFCgye/wCNS6g4Kqu3AJyPb/OapqrMdqgkn0oA1NP+eSNFILK2Bjvina+pedf7442j/P0q1oNtvuAyxhWA44HtxmoNZty15hzkn5iRQBn6bG2SdpwfQZ+uKtzttDluMewH6VatV+yWpdU3HGADVSbLq2ScnOcd6AM2OFnwBxnpk9asRBY2UrkhuDuIxxzmhSIYpFEgz2x1qFFLNgFSCeMev0oAuqCZWY5wOMGriqhZC5BJGMA+3FZtlExc5POcbfU1qyptliWJz1OB1280AW4N7sECADoOK2o3EEGFOH6cDGen5c1Xs0jt4mkmyzY6dKqTTM7kgsF7DNAGvb3jGM9GPTOelQSOQrOeTyazkl2upJwMjJPJ/OrepOEtXIZiSOSOOaAOO1Rw85cPu5Oe5rA2+ZL8u4gnkkVp3LNLPuUALkHJ6+lRxxrEmBzjPOOaALUEA+QMwVSOBnn2qvc2yhnkTICnGSeMgd6sxgyugRug7/w4qS7UyxgHaxOcY449KAOdxgnnNRyGTAKDnJGD0IqS4Rk3LtDMO1Z4d4nDEcEfKCc4HagDStp2Vcr3wTx/n1rb8Ja/eeGfEGn6tYNma2cOY+gZO6n2IJ/OuZFxlBvYox/2e3qKvCUeWEHBP3iefpQB6n8eNDtWvrDxloI3aNryeYzL0ScjLA46EjJI9Q9eRupLht2B0Pbj/wDXXTr4y1NfAz+E3+zyaW1wLhC6ZkjbrtQ5wATk9M8nnk1zTA5Uoc89WGDigCJ41ZyXO5f4QT3zg/0pYkgE0fnAshJJYnnj1qpIzg9Nu1iMrnFPY+YpMknA4455z1x6UAeh3HxKnsvDcWhaMv2eyUl2bGSx9cfnXrXwE8ZahqVuYVTfAv3iR1+lfO3hTR31nUfs8cbSH/ZXIr6Y0Caw+HugJFHGouZeWGPu+g/U0Ae4RksisepANOOccda5zwbrq6zYqzvmUruxntXR0AfMfxi8RXN5qssN7EphVtiggdPQV4r4j+zzzb7KIqg5x2avoT49+H/s16b6OLMc3OSDjNeH31qkYV9oJYfdIzj8aAOajRMKpO/H97t/nB/Kimz7hOpQZKjPJz146UUALaoRuywY5zwTU5HPfnrzTIF2qRknnH5cVcg+U5A3IzBcn/D8aAEitcIXb5V5YjHNNnfc2FbK+g4H5Vc2/umUZUH5eeOP8mqDkuwbgKBjAH5UASWp3ZaRmRiegPPepUjMjFXyXX+POQOelU4yQdytkZyD6VuaXG81zGrbPmOQF/zzQBs6VhbVYHA5OQv/ANam3UxIAO0BeSc54p+osIc4BHGWHQcdKr6DE99fJbnJDH3/AJ0AdDoWmNLGJeDuHGM1py2/kwbgSzdAPf6mujW2Om2KKF4AwO/PvXMzyKTuDMcnoeOfbmgCrbnMkuA3Xv0HtWbqaI8jMSQFPUD6ZroI9osXlZOf9odBXO3ameQNzjdkjPagDEv0/dq3Uj07ZqGyz5p5PAzgHrWjqNuzDKlArdAOlZSfu5PnLrx/D1oA6XTZDZOHLAyOB8o4NSX4hnBbG2THUmsYPzgFgccN6/So5JTGSDgdwcZ4/wD10AWLq5V3IL49BnpVKK6PmEPtwe/QChZPMkd0Vc44JwNvv71VBIfLfXkZ/GgCaSQIAIcAHk9+vakt1LEFRyDyS2BimMqqOMMD0bpg1Jbbw+zHHU+o96ANGCMPId4cjHRK0bVfNn28BVOwADJHvUNsDFCWwGJIPB7en1q5p8Ti7LkjBycD/GgC3qf7t1jJ6YJ+pql361c1VHE6lmUkgc9c1WjCOpO75uQB0/z3oAWNDI4RSq59RWjqMDXNliMZ2r6d/wDJqtYxFC2/O8DB9K6TTrYXNm4UEYXr/OgDySRCkhU9qYABnHfmr2uw/ZNRlRuOeB0/Cs2xkE8m1gQM+vrQBcgLAEK5xtOADnJ9hQ8shjw65XPVh3qZkymzATB6Dpzx9TUd0wZBhT8rFfYUAZmpxiQF9q444P8A9bisWRAZMgrhs9ORj+ldDMA0DcsODnArIlVQBxwONy8YH+FAFSaXaTtOW7OB1HSoFLFsKTk8daChBJwRjGc8U3nPtQBbjuXBIYKxAPtU3noBuLDPTaD71n0AkqMgA/yoAu4MkmHTKnkHfxj6U6S3jEZC/J6nrVSCUxPkdD1q9JIrJhtuzo2e3f8AGgDr/hvLdaZf/bbN8bCCHY9B/hVjx98Qb/VddjWBQNvyuy9q5nQbtzOtrbyYEoKemBW9daDFYXAmyXLHk44oA9B8JeKLjTra0RHbzWGXY/w8V9CeDtfj1ywyWH2iMDeB/OvkuC5aDTLl0y0w4SvZfgPrkMEQsrli0838fUA56UAenePLKwvvDlympBNirlGPUN7V8l6lBYLqEsMk48vecMCMDmvq74h6UdT8OXZWRlaKJmC9QeK+RLXw7LcXMtzeP5VujHGTjnP/ANagCvf+GHwZbNxPkZGD+JorWj0m5s1a80u6Eqx8lQev+f8AGigDhCCT8vTPfirSq0e2TduOOQQflH4VBbkpIu0kev0rQ7LswcYPJzxQAxnUvgrkY5z2H0qlIwkY7QFUZIAHJq3dEBQRnf8Aw4H9aqSxlMZ7jt60AJs2GPAGDyARgfSuq8NoiX3nSEYAIwRXN27NNOPMwwAPWt+wIEDYyc5z/n8qALN+VluJXIBDdgcjFbfgG2EV60jBXI9RWfBCj28bOuckgGui0CE2aPNt2jBwO9AHQ6tqJMbhB04wTxXHT3AaXegwcceg/D8an1zUWPy7DtPp6f5FZ1uPPGYhnPJ7UAXriZ/mhILIBn9Ov51nzlCCrHAzgcdf0qVom3OF5C9SKUpgMP4168jGKAKF1EMjYvJ7Af59qyHtTkszlh1J71uXuDBwvTHf9ay2U5OWJVuCCOgoAqiVfMXJAQMSBjjH+P8AjUMmN5+Yv70SLtPoe49KibOQRnryBQBO/wApYggbh/CfpkcUkbIrA4OR6nP5e9MyABjr3yKVMb+Vz6AUASB1Z2ZwFyCVPv2qxZYMxMRA44B4IpmNmNkR5HO0nI/zxU8Uaj5xksepOf60AaixK8CbCQMeuRWnYxkKHLg54PFU4d+0RZBJ6AAeg6VftiETy2ADjPHc0ATX0DvAJCVC9eOn6VR0+BonOSdvO09Af89a04lknjEaKcEhuR0NQ3MiREI2CckNQAK6l8JznkkdBXQeHZWLhAxI6EH0rlLfcshMf3TyQeOP1rc0x2Eiu+MoMcD1oAyPibo8VvqP2iAA9yT246V57aqRuYqFDcjH41674v2X9iNuN6DJP9a8uEGyfZtyM5OB1HrQBNAG+douADwM9fai8fMag4znPB6VKFClQFYKR15z7Z/+vTLokqSgDcYY9cYoAzpHSNMnGBwB71kOPNY7kXIb+I5JHrVm4n81yoPyr0H9arrKCwXGSVBGKAKphaJckA5BBYdqrMMAEYJIzWjONwACBmOcZHFVnjM8hMeRjg7u1AEAUlSRjA96bjIGcGpXjdcpwdvzHFR0AJGoEgdVUk4xx1qxL8xVuTu4B659eKrDC7VVePbtTsjpzxz0oA1NFmNneh+q4z9R2rs7WQ3sZmckJgkegrz61bEgBL89MfWvV9G04XPhma3ttzSMvUDn/P5UAcle+IUjdowFWLPAA6+9dV8IdWnu/Fltb2g+dnAAGfXpjFeXa9pk1nqQDnC56YPODXuH7KGhXs/iKfV57ZRaQIwRyO5GPzoA+m/EUrwaJeGOJ5nMZXavXkYzXw98RJtetLyZbkSxQByEQZwB/k1951xPxI0fRr7TDHfWsJuJCArkcqPWgD5B8JX9zZWomMrAHnaTw4orP+Kkq6TrEum2IyiZGQDRQAy1Cjcdv3mwee3vVqRmVeASMdRyfyqOJTvGchlUjPUHn/PFWPpQBHjzE5HTjDden6VFKm4Lu52/dzxu9vrVg5AGOTUW1mjYycN6ZwBj6UAVYh5c3zNs56jp9K2bOUDIYlQcYyeB+dYt3dxRkr8pKgYwc4PtVW21N2O05A4wQR0xQB2dtfLE6/Odp9cj8RXY6C4v4xGuG3/xdM15vY7rgr5fJ43Dqfyr1z4e2H+kxBgqbRyemKAOf17Tp0mEXUA4Ygf1pllB5NuSxYpjB3D616xrGh2aozK2ZTyx4xXCanbv5ckKRgE8KCegoAxIZDMf3YwcfOcfy/WiOJZYjvU5yfmxgnmrMNjJAjSSEBiOSTTVGFAwB7CgCjPZP5a4P3uD/tewrLubZg7MuAvcdMVt3lzlwB0DZ24xj/PH5VmtJtVmKsAPpzQBkPAhY5BU9DjjPsagktxz5fK55XP+fWtaO3DyMWcNg844OfenNagkBMcnJJ4P4UAZf2dCn3AGPPXpSWtqyvl8cdD/AFrbNugjUNGAD3x1qrJEyCTDYTjryaAI44g+VXO7PX+HFWY7NQwLMxA5OBSQgRxLucjJJAHftTrQny8EHIODk9KALsEG7G7Krxjtx/n+dXIYvLdzzg+p61UiuCoUNyF6cc1eikDruXIzxzQBbtQYV813ZQDwOmfSs2/aMyuy/wCs3fQjvV9Asrxq+FXHG2pY9PkbKx7STyeaAMGIN5hVW2MeOePwro9DizJtKll4AH09aii0t1mYFCMk8jqa29Fg8syMMBEHtye3NAGdfRqzS27fKx7HvXn95C8F/Kh3YA+UHgflXZ6/I0Vz5kb85H/6q4zWLhhNu/i9T3/zn9KAK7PtZgQqf3S3f1rOv7nCny9xUccnP40+4vEZNr4DDqcdPaqzItwoO47fQdjQBnU0khwP4e5P6CldDnDD5fQjrR0yeT7UALVWXdHM7rgtt6e3r+lWqUAk4HWgCgEaYhwQHPPXGMcVCsaFHBXDLzk/XpWmYs7mXhj3B9vSoDbLg4JLEg5bmgCjhiM8Yop7qqllLZI6YHf3qLGJCCwOckYGM0ALz/CcHsa9R+CuqudYjhvFfyWx8pFeZRSGNsgAjuCK9K+F8lq+p2/mOQdwbrQB23jjwcJJ5L+eLy4Nx2kjAOawPCvjy88K3P2TTpcRMxDKtdD8c/FsmqXljptmWitLZMMOhY4xmvIYgr3bFA7SjnPXBoA97k+LupwW++B97nruAYD86xtP+J194n1Bk1TaiqwRFUAA1zPh/wANXWt6RNcWsTu0fLqB0rNfRJ9NdpF4bPUdRQBe+NPw3uZ44dUskDiddxxzg0Vmr4q1u1vY4555JLeIfLG/Ixnj9KKAOeUbVAHQUpwFySPf2qDzFhjXdk56YOeP8ms27vHaQqQdnYDsf/1UAaUl0ijCjec/TFZdzethQGyMYI+nqPrVZ52O4KMdFAyd1RqhkXOGZu5zk96AIyJLh9zE5AyRnFS28LRPGGyoHAOfSpI0VMHK7/l+VucGprS2zJ8xyxOMn60AdFoMqwESuw4zxj/Oa7TTPErEhI1AUHgqMHgV59BE0GQWUp1JPB/wra0ghpNn3WHII6mgD1nTPEIvZVSUscDB78+taDpFsaRSHx1BJ7mvN4roQ/Kr/PxhcDr/ADroNF1eQTrG+RnBwenrQBJqSyOSSHDE/dA6iqADGDnp2Cnoff8AWtfUrt7lZMLgN0GM1hqMDGSfc0AZ12PnbAIbvls1mmTcG81CR9AMH/OBWpdjzCxIwOmDwTVC6H7piFxjv65oAICPMwhXb0wF9PetuGJI412qA2OeOntmsvSY43XkNn6da0LqZoiAu3kfjQBFebSwJYnsAOgNUgUUseB3JJqZ3dwTn+HHrx/+us8RMZmCHDDPJz/nuKAIpn3zMwJx0FXYW3RIctkgfp1qiQVzlSFzg5GP/wBVaFqjMqqqrluTtPGf8igCWJSzovByea07eLMir3Ocew71VjhaNwW+Zh0X29f1rYsOj+vFACYXc0cYMcm7AwTkir9kNk4YnBPLc8dKjdgoBYqB65q3byQS23zOgxjIGcmgDSnuYJWIQgnIBbHX6VS1J2RWhQSIjjJJ4JqjLNscyFguDwRT726/0UySsC4OOfpQBieJTGtmqry+3ksefT8a4bUipRdz4PTr2roPEN2HXO1mIOcjpXE3E7ZeNhzjA5/z2oAjjhd2zJkZ9eT/AJ6UgkeHcBkHnPHGfb070sLhnVduACMd+/f+WanuU/dEIAqj5jigDOkkAkG/OWPXHGaagO87gox0AB/n+dV7zdjkfiOmOw/rTrOQbQmTkdsUAXVVW/jCn3HFGOCFwfUg9R1/pSRxl+EBJFXIkXediKQMYYnJ+v8An0oAZLCvlbhjPUY9PT3+tVWR3xt3EZxnHUelawI/Km4wxO0cdMfrQBiyQKwYADnnPp/nmqphCgKxweTu6Adq15PK2kgEnkjAwAKgC5JwOcUAUFheVT8qqRznHX6Y7Vd0S4nsNTi8ncX3AfKfoageOWNtwYv3wRzzXQeA9MludVieVf3O4MSRnB70AdX4vsbn+z4NRnjbMo43Dr+Ncz5SwGN1VvMflh0/l35r1j4pa/pf2K00vT0BMUaiR27H2FeSahcKpWQZIUAgZxzQB7T8BfEkdvLqllcREp9mZyccDAzg/XkVh6BqdlrLXXnn5/OZdg4I9MVufAGxtf7J8Qa1fpstvsxhLOOOc5NeZadZyWmt3FzZqxtXcsCOeT/kUAb2teHZJJm8pd65znbnP/16K7nwZqP2i8RZLUztjOAOtFAHzfGzNz8pU9CDTJ48/OCAR1J9Kci44X5VDZwBjPFSEEuNvC+hNAGe0LDjG446Acjp/jUhTYoLyDcuQAvH61cPpyM+lRy7zuUJlSCOuKAK8KiSbIzxhuefwzmtayYDI25f+nFU7dDEgDksP88VdslByd3PIwPSgCyyBlYH+LqRxWrZoYUJzhjyCM1nwqu4KQxHscmtFAABuGG9c9f84oAu20Q8tpH6YPHtVi2uQH3ISpPHLZ/SorHBU4JyDzzUbQO8xO04J6nAoA6kSnyxzuc87v8AD8qrhX3k7/lznGKSxzJEoHLDNTEZJ49+O1AGdflgwAcqv3iG5FZzxs8wDAEDnBPYntWjeQEtJnJQjOTUa2zMBhOVOB2IoALSTynA28bQP8mnTs7OPMxux09Kl0a2YtICd0g5y35U+SDzJZDnnAI5/wA+lAGY1yRLtPC9C2ePb+VKHUsHXO05yc9PfH4UtzbASFnLKV7j0HpUEUO6FWjcqT1z3oAmMccoyVJ571q21qITx8xA446Vn20ADbFOATnk10VgCAx3DHAPrQBVCsxYgE+tWJ5xY2wL9epGc4qxEroGMrA854rn9Xmea6+UrsU4BP8An1oAqzXpu5JCxZEzkEcCpY5miYbXIwc4zVCVlXcqKA3IwOcjrmoTIS6sSMge9AHSwajtVVcLgc8jODVO6uTKwAY4PUE9axjM55JO719PpUkTswEYGWY53E5x70AJeF2G8bWQZ24PWuW8vzJnMiE8/Ke3FdPcIVhbdkjowPUnFc9NHh1ZWbg/dXoTQBFHAySKdq4zknP6VLcHET5zjHb1p/HTAI704ooQKefUHmgDAvYxsJbcCD06/wD6qgtkbzhgkAYzj6ZrUurcEMScoTx+NUo4CsgJbpz+JoAvW7sDtUfKTzgZzWlbRG4lSKLJJJXAH8qzoxIigqGx97OOn+PFb2kPsJkdcNyAOCRxQBHFpkjXTRxhS2MnAGahu7fyHKyMDkYxmtNWKSPIhxI3U/8A1qzbr5pCxfcW5OOooAqGQmRFUrk5IY8jHoKjhjUMZHUgjt7/AEqaNCpOcleo3HJFJKA6ugGWK/8A6uaAF022ivLqTzQQueMHjr7V19ndRWaGKEBGXgP3965/woiLeMLhTubPOAMV6EPDccmjxzRpmVzkkDjH0oA4DVZXkuPMJPzZxn/CtHwX4Ru/GWqCwtkIUHLOegFUvENvHbuxR8kDGAenFb3wZ8azaVfz2tuigkbfMBJ/l0oA908W6PY+F/h3Z+GbZlj+1MI2cfxHuT+lcnf+HrbSdPhgUqytxnOf1q/48vbjxJZ2MrKU8ojDYx+NdT4I0TT9Sgjlu5hcvH0Qtn/IoAw7W0bw5oEd7ZwKszJ8shGccUV6Nqkuiy6VPbNcWvlRLkqjglfwzRQB8GIcgjJJ6Eg/pxT+MdK5mDUxv3IV68e1Xk1RnbZjbk8HFAGvSw5eRQF7jGRwaz4Z2kKKzdT1xyD6Vowgb1HXpgHv7UATRKwl2HcPYnjH9avKCBjgew7VAEUkja3XjIPB9sduKsAdAMn0oAt2kYOGIBIPrnip5ZGDL5YU7uQM9arwuiQhj94dg2CeaRC08ihk/d8kDoMUAbFjt68b+hHWrjE+ZhV+X1pulWpkiZ8Hk4GOprWj01pVByS+SDj/AD1NAFrQLZpPLSLaC3y56CjVFe31F4HZZdnBkj5X8PWtJLP7NbqBgYwMD6VS1BIw4MYI3Z5NAGc0hEZJT5sE4B/PmooZJWKnC7XzjjoadKx+aNgFDfdx1aprNTJGAgOR2JzigCSyWYwyS4ZCvP4d/pVizgVlZpBuJ6H25q1qTx6dZJCyMXlHXpiqGiv50jtKyooB5oAwdVbbJIoZSu7BPU/h+VR6ewCDdlgpzjHH0qbU3b7TL5aho+Rz19KqxTsyMH5LZC44IoA1TKskynazEcqo9a2bAjBxjcDzx1FYNs4VdxyrHgk8gf8A160dPkUMoZME/wAHTB9cf560AamqbEtt/ADc8cjrXJXUcc9wXO7kcAmuou9hgIbkdB3ya44M32tgRvAPTHT6UAWFQbt7Bd/qKozq0Tlc5B555z1rQdJBEWIKE98ZFUr1gxTAIOMnIoAqkEMu3bt5z61IEYxl8fKDip1tyyKx/iwMAdPf/PrUsEIUvx7K2efegCqXP2byyOpzknp9P1rIljImKqWY88Ec1szJtITO449e/FX9K8L6pq/FhaOxP8Srz/k0ActHGWYhR8wyTx/SpJYCIQWzuzjANdZqnhDWdGcJfWUqM2Ooz271Vm8Pan5SsLNmZvuZXkUAcdefdA4PfntiqqwOygqAQRkc12994O1S30t7me0mGRzuByPWubkheFysiOrA5IOeKAKQtmRwwIOOnuf6Vo26qkbSuM9gG55qJVleTZFG0jEcBR710+h+BfEWtSKLbTZ/LPRypxigDEt7gELG6g/w+2MUy4iYb3YA57g9K9Q0L4I69dahs1Apa2o5LscnHoMVT+KXhBPCksUKTGYBA4bpzQB5l26Uh4GcgDvmngvPIMKzOxwAF5P4V6J4P+Fes+IVSZk8mBjzI/A/+vQBmfD7SI7zUFaX/VgbiTXbeL/E0NjpP9j6NGqJyHmOOT6CvUPB3wx0vw/YmO5Y3UzD52PC15h8SLDS766e20iDbBC20yqeG/z/AFoA8K1mK5nvDErmQkf3eea9L+AngO/nu3uHh2wk5+foRXW/D7wRp1uP7Q1OLz0P3F64r2TwYFPneTbJBAoCrtXFAHLfFY2mh+DLe0cok0j4EijnI/z+lfO+r65q2jQGWzuWRXUgYJ469a+hfjzol1rejwJaLuaEF+OvvXg914K1zW4LO3is5CcgsAvFAHmemeMNYXU3hlnY+b975veivavDv7Puq3GrCXUAttCDk7j247UUAfLNSxyyBxtYknA55zS2ltPeXMdvaQyTzyMFSONSzMT0AA61pw+Gtbl1qfSYtIvZNSt9wmtVhYvHtGW3AcjA5oAl02diyqwBBz8uc4/KuojJUJIpwWGRXE6TBdXt3FbWcMk8sr7EiiTLOx6AAV3nha1vNWnFnZ2U91dBWLQxR7iNvU+wAzQBbiYPz/EQMj0HapQoKkkgY6cd6rrCo2vGTjqBng9f8anUE4HAP1oAVXADLgHPfHStnQrF55DnAThgOuaytvkyL5q54ziuw8Ix/aLiEBSdxyRn6UAdT4f0WS4YFVyFXgHitFrFUu1RvkKtg45z6V0kMQ0u3jRVCSEeuMnFU43FxcurMwbOeBn8KAKmpxL9nVEG0HqwPfFcrqLBYVCliTyR6/54rsdViEW0E5PY1zOoQxlmAHbPHagDmJwSxdwGXpuT+ddR4PtDeXSLIBknnjGKxoo8ybBkZPT0rvNJtBp+kyTRJiVlJ60Acb40x/bLwqzSeXkDBzVHSdwWUn+FSV9jT9WmLXUkrbVkyTg+/eq1gjCORzIGLHnnGB6UAZ1wnmTS4dsHK8nI9iKbAp3lXwSAAg4J9M1eRUYOu0o54GTx6j+VQNEVbkYySM54NABk44YnbyMdq0LdgyZy2Sc/Mf5e1V4cBR5g4VsdfX/PB96t2sbSPtjC7AOMHP40AWVVZIPL+6x4znr+FZraUY5Q+CCflOB15rp7aBDIrsgIHAx/Knyxhp1RQAehxwPy+lAHLahbyhgpViAOxOaybxWGJFOMYz/T+ddhqkJFwAoyTxwMe9Y8mmT3KtDCnzcYyvOKAMpZ1dQq5aQjG1c9a6Xw54F1zVAZUtnWNuQ2M5rvfh18K8hLzWk2gcqp6mva7aCK2gSGBAkaDAAGKAPGvAfwiMF4bzxHhlBysIOd319K9is7G1skCWlvFCoGMRoBxViigCC5tLe6AFzDHLjpvXOKclvChBjijUjphQKlooAbJGki7ZEV19GGa5q+8CeHL68e6uNMiaV/vY4Brp6KAOcsfBHhyxmSW30m2EidGYFv510SKqKFRQqjgADAFLRQAVzfiPwbpXiG587UkkY4wQrYzXSUUAcjpvw68M6dcCaDTkLAYw5yK61FVFCooVRwABgClooAralafbrKS3MrxCQYLL1x6VgQ+BtHjs3txHIUclmO7kn8q6iigDL0rQbDTbcwQRFkIx+8O7itKKNIkCRqqqOgAxTqKAGvGj/fRW7cjNEcaRqFjVUUdlGBTqKACiiigD87fgNr83h74naLcRXEdtDNOkNxI+MCJmG7JPQYr2/wH4ugs/j18QoTqlnHod6JpjM0qiOV1UBcMeD/ABdDXy3aKgj3j7/OSTgVdjDM2FOMjk5xxQB2fwqNro0+s67ctEr6bps0lqkjAGSdh5aYz3Bfd9F9q7/9lbxKdJ1rVNPu76K106a1eRjMVUM6j5fmPfk15AsB8rcE3I3zEjkH3qJYtjqULcH+9igDp9NcuducKecNxitnEccDMigP93k8g1gaWrP5ZAYnpnB5J+tdEA6wICm5x0HXHvQBS3My7S2R6E16T8HtNNz4gg85iqL1JrjLKxaaZFRSFPRSOM/h1r1HwZbvbzxxQqAxxvK+tAGzrc0jeIp0Q7kQ4XHOPaqUUnkXPmqvz5ywPc1r6nGqSuIU/e8hm6ZrnDIDP5eSAOeM5z/hQB0l6WvYS4QZxyynj/Peucv4PNVuPLYKf88109rGx0wEMAAO3cY/+tWdcJEy7mIBxnI5+lAHK6Zaut2GYlmJ6da7G7lWHR1jDDzDwVAyTWHYWzG92YO0njnANX9dIj3Rk7iq4z9aAOI1SRHd38v5QcehAqtDhrVljHPI54zV27QbmD4O7nAHr61Xgi3wny8xqeT82O9AEUdqWO0j5s/KwOPpUkkT22EJZjn1AB/OrPzIiyICAO4Izmq9wV2LuAGCcH14PWgCCSfKsGQlDx0xg+laOmhfJDISB0APAJ/zmsmSUy43jjoB0Ga3bGENCqoD94kAHv60AadnB543oTlSPu81GZCbwYQcNg9P85rSt1eKyk3qAo/iA7Uzwnod5r2qtHbxkRIclz0UfWgCRNMuby4iS0jWSVh6fzr1nwT4Rg0W38+5jV72QZO4A+X7CtfQdCtdJiHlorT4wZMfoK1qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsq/wBfsLC4MNzIysOpxwK1a8O+PAvra6D24byHTczAdKAPXjr+kiF5TqFsFQFjlwDjGehor4Q8Ua9PCssf2l1IUjGTz/nNFAHmlvKIm5Pynrx0qf7XH6N+VUaKAOgTX0SLYLdnz1y+P6VVfWWLErCqj03E1S0+NZblVkGR6fiK7SzsrVYMi1gJCA5aME5yPUUAQeHfEtp5kVvfxNEOAHQbgT7ivSo7aNF3uwYdvSudsHEMJMUUCnYDxCnt7VHNqt41x5Rm+QkDG1fb2oA7rTTn96mPl4DD1710WmTy2p3o4Dv83X6V57p+oXKwELJgBv7o/wAK1bDU7wq4M3Axj5R/hQB6vp8zSwSO8i7sYPfOaxJGjW+2vgSnjHA5rF03Urv7O/73GVLcKByDx2qEX1xLqcbSSBiBn7o7n6UAeiQ6jCLAwKoB7k9hVaLYYsIAUPrXP3VxIs7AMAOOAB6VYku5orWMxuFJxn5R6UAXVR7bUo1Eg+UnPH3qu6/ZJIgkEi/MueB3ri7y+uTckmU5HI4HpUunX1w9oN8pbPqB6CgCleJHGh2kl/QDmq2mpl/3rHk9GGM1XmnkN5gtwWHarmluWeJmOTz2oAk1DYCQU2J09BWdLM3Hy85BU9BVnW5X8/GRg8YwPasmV2aRSTkscH8jQBchkZ5sSkDsBjg57fyrodDEkkgES5JO3aB+dclExMak9SK9R+Fscb3025EbYvy5UcUAdb4d8C3FzGk+ouYI3/5Zg/MRXf6RZWunRG10+ARwL1YHqf61kNfXL3FvE0p8tjgqABmunAwMDgUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZZEijaSRgqKMkntXy9+0d8U3kA0XRwvlDPmOR8xP8ASvVfjRqd7ZaTMlrcPEpTouPeviXxFdz3V+xuJWkJAOW9aAMe8nnmDtIRICvDZ5oom/1L/wC6aKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow in a 62-year-old man demonstrates a dilated barium-filled esophagus with a region of persistent narrowing (arrow) at the GE junction, producing the so-called birds beak appearance. Achalasia was confirmed with manometry and the patient underwent successful dilation of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow showing a dilated esophagus and birds beak appearance typical of achalasia. Retained food is also visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ram Dickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41538=[""].join("\n");
var outline_f40_36_41538=null;
var title_f40_36_41539="Lincomycin: Patient drug information";
var content_f40_36_41539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lincomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/24/43396?source=see_link\">",
"     see \"Lincomycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lincocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lincocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very loose stools (diarrhea). Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lincomycin, clindamycin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12031 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-C12E3FDE9F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41539=[""].join("\n");
var outline_f40_36_41539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188812\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022228\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022230\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022229\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022234\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022235\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022237\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022232\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022233\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022238\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022239\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/24/43396?source=related_link\">",
"      Lincomycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41540="Magnesium gluconate: Patient drug information";
var content_f40_36_41540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/10/34980?source=see_link\">",
"     see \"Magnesium gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36676?source=see_link\">",
"     see \"Magnesium gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Magonate&reg; [OTC];",
"     </li>",
"     <li>",
"      Magtrate&reg; [OTC];",
"     </li>",
"     <li>",
"      Mag&reg;-G [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low magnesium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium gluconate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11216 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41540=[""].join("\n");
var outline_f40_36_41540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012374\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012373\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012378\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012379\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012381\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012376\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012377\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012382\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012383\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/10/34980?source=related_link\">",
"      Magnesium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36676?source=related_link\">",
"      Magnesium gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41541="Clinical features and diagnosis of insomnia";
var content_f40_36_41541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of insomnia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Michael H Bonnet, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Donna L Arand, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41541/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/36/41541/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia may be associated with a medical, psychiatric, sleep, or neurological disorder. Alternatively, it may be a consequence of acute stress, medication or substance, poor sleep habits, or changes in the sleep environment. Finally, insomnia may be an independent disorder. It is therefore not surprising that insomnia is the most common sleep complaint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation, clinical features, diagnosis, and differential diagnosis of insomnia are reviewed here. The types of insomnia, its consequences, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311471\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311479\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia complain of difficulty initiating sleep, difficulty maintaining sleep, waking up too early, chronic nonrestorative sleep, or poor quality sleep. These complaints are accompanied by a report of compromised daytime function. Although insomnia is often a presenting complaint, it may also be reported during the evaluation of another complaint or during health maintenance screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sleep history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A good sleep history includes detailed information about symptoms of disturbed sleep, the duration of the symptoms (ie, acute or chronic), and the sleep environment. It also includes information about sleep times (ie, bedtime, duration until sleep onset, final awakening time, nap times, and nap lengths) and sleep problems (ie, number and duration of awakenings) over both a typical 24-hour period and week. Patients who cannot provide an adequate sleep history or who report considerable day-to-day or night-to-night variability are usually asked to complete a daily sleep log for one or two weeks. Sleep logs record sleep times, sleep problems, and subjective sleep quality, so that the clinician may review the information for diagnosis and to evaluate treatment efficacy without being misled by recall errors (",
"    <a class=\"graphic graphic_figure graphicRef87134 \" href=\"mobipreview.htm?4/53/4955\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87859 \" href=\"mobipreview.htm?13/62/14318\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with insomnia describe difficulty falling asleep, difficulty staying asleep, waking up too early, chronically nonrestorative sleep, or poor quality sleep, despite adequate opportunity and circumstances for sleep. The degree of the sleep disturbance reported varies, but typically includes 30 or more minutes to fall asleep or a total sleep time of six hours or less on three or more nights per week. Patients may also describe variable sleep, such as one or several nights of poor sleep followed by a night of better sleep. Occasionally, patients may report having minimal sleep for several consecutive nights.",
"   </p>",
"   <p>",
"    These complaints are invariably accompanied by daytime symptoms of insufficient or poor sleep, including daytime sleepiness, fatigue, malaise, lack of energy, and poor motivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/6\">",
"     6",
"    </a>",
"    ]. Other symptoms include inattention, impaired memory, poor concentration, mood disturbances, irritability, headaches, tension, and social or vocational dysfunction. Patients may be prone to workplace accidents and motor vehicle crashes, and they are universally worried about their ability to sleep.",
"   </p>",
"   <p>",
"    The sleep history may provide clues about the cause of the insomnia or factors contributing to the insomnia. Patients with poor sleep hygiene may describe irregular bedtimes and waking times, while patients whose lifestyle is contributing to their insomnia may report exercising, smoking, or drinking alcohol or caffeine shortly before bedtime. When the bedroom environment is responsible for the insomnia, patients may describe recent changes in light, noise, or other distractions in the bedroom. Patients whose insomnia is due to a primary sleep disorder may report symptoms or signs of the sleep disorder (eg, loud resuscitative snoring in obstructive sleep apnea).",
"   </p>",
"   <p>",
"    Patients with insomnia due to a stressor (ie, acute insomnia, also known as adjustment insomnia) or jet lag may identify the stressor (eg, job loss, death of a loved one, divorce, argument) or report recent travel; in these situations the insomnia is often present for less than three months. In contrast, patients with insomnia associated with medical conditions, psychiatric illnesses, neurological diseases, sleep disorders (eg, restless legs syndrome and obstructive sleep apnea), medications, or substances are generally older, and describe insomnia that has been present for more than one month. In these cases the onset and course of poor sleep follows the medical condition (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"mobipreview.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Independent insomnia disorders include acute, psychophysiological (ie, primary), idiopathic, paradoxical, and unspecified insomnia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    .) Acute insomnia was described in the preceding paragraph. Patients with psychophysiological insomnia usually report difficulty relaxing, continuing thoughts, or being worried that their lack of adequate sleep will result in significant compromise of their ability to function during the day in both social and professional settings. These concerns can create a cycle that worsens the insomnia; when patients are unable to fall asleep rapidly, they become increasingly concerned about their performance the following day, which makes it more unlikely that the patient will be able to fall asleep and sleep well. Patients with idiopathic insomnia have lifelong difficulty initiating and maintaining sleep, resulting in poor daytime function. Finally, patients with paradoxical insomnia consistently complain of insomnia even on nights when polysomnography reveals apparently normal sleep; such patients consistently overestimate how long it takes of fall asleep and their total sleep time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia may report coexisting medical conditions that are associated with insomnia (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"mobipreview.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ). Among the common comorbidities are chronic pain, respiratory diseases (eg, chronic obstructive pulmonary disease [COPD], asthma), heart diseases (eg, heart failure, ischemic heart disease), rheumatologic diseases (eg, arthritis, fibromyalgia), neurologic diseases (eg, dementia), urologic diseases (eg, benign prostatic hyperplasia), gastrointestinal diseases (eg, gastroesophageal reflux disease), endocrine diseases (eg, diabetes mellitus, hyperthyroidism), cancer, menopause, and dermatologic disorders (eg, pruritus). In older adults, difficulty maintaining sleep may be a consequence of normal aging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7671?source=see_link&amp;anchor=H2#H2\">",
"     \"Sleep apnea and other causes of impaired sleep in older adults\", section on 'The effects of normal aging on sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychiatric illnesses are also common among patients with insomnia (eg, depression, anxiety, and posttraumatic stress disorder) (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"mobipreview.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ), although it can be challenging to identify psychiatric comorbidities because patients frequently deny or minimize the role of the psychiatric disorder. As an example, a patient might say, \"I would not be depressed if I could get a good night of sleep.\"",
"   </p>",
"   <p>",
"    Patients with insomnia may report using medications that can cause insomnia, or whose withdrawal can cause insomnia (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"mobipreview.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ). The former includes central nervous system stimulants, beta blockers, bronchodilators, and glucocorticoids. The latter includes sedatives, hypnotics, and glucocorticoids. In addition, alcohol, caffeine, tobacco, over-the-counter medications, and illicit drugs can contribute to insomnia and are commonly used by patients with insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of patients with insomnia may reveal medical problems that are frequently associated with insomnia. As examples, excessive oropharyngeal tissue may be seen in obstructive sleep apnea, lower extremity swelling in heart failure, extremity deformity in rheumatologic disease, and an abnormal mental status in dementia. In many cases, the physical examination will be normal even if the patient has a medical or psychiatric condition that is associated with insomnia (eg, asthma, ischemic heart disease, gastroesophageal reflux, and menopause).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is a clinical diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/7\">",
"     7",
"    </a>",
"    ]; therefore, a sleep history is the only diagnostic evaluation that is required to confirm or exclude insomnia. The sleep history should elicit a detailed description of the sleep problem (ie, number of awakenings, duration of awakenings, duration of the problem) and sleep times (ie, bedtime, duration until sleep onset, final awakening time, nap times, and nap lengths), as well as any symptoms of disturbed sleep (eg, daytime sleepiness, fatigue).",
"   </p>",
"   <p>",
"    Although not required to confirm or exclude insomnia, all patients undergo additional evaluation to determine whether the insomnia is associated with another condition, medication, or substance. The evaluation typically begins with a medical history and physical examination. Patients are asked about the symptoms and signs of medical conditions (eg, wheezing, dyspnea, peripheral edema, pain), psychiatric conditions (eg, depressed mood, anxiety, and suicidal ideation), sleep disorders (eg, snoring, restless leg syndrome), neurological diseases (eg, memory loss), medications (eg, stimulants), and substances (eg, alcohol, caffeine, illicit drugs) that are frequently associated with insomnia. The physical examination should be broad, looking for evidence of any condition associated with insomnia (eg, wheezing in asthma, excessive oropharyngeal tissue in obstructive sleep apnea, and lower extremity swelling in heart failure).",
"   </p>",
"   <p>",
"    Additional diagnostic testing is based upon the history and physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polysomnography &ndash; Polysomnography is only indicated for an insomnia complaint if another sleep disorder, such as obstructive sleep apnea, is suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=see_link\">",
"       \"Polysomnography in obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple sleep latency test &ndash; The multiple sleep latency test (MSLT) is not a routine diagnostic test for an insomnia complaint and is only used if another sleep disorder that produces a complaint of significant sleepiness, such as narcolepsy, is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35095?source=see_link&amp;anchor=H4#H4\">",
"       \"Quantifying sleepiness\", section on 'Multiple sleep latency test (MSLT)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric tests &ndash; The Beck Depression Scale and the State-Trait Anxiety Inventory may be helpful if a psychiatric illness is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Beck Depression Inventory for Primary Care'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38553?source=see_link&amp;anchor=H32457457#H32457457\">",
"       \"Comorbid anxiety and depression: Epidemiology, clinical manifestations, and diagnosis\", section on 'Rating scales'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Actigraphy uses either an activity monitor or a motion detector to record movement. The absence of movement for a predetermined continuous period is suggestive of sleep, while sustained movement for a predetermined continuous period is suggestive of wakefulness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Actigraphy would seem to be a helpful test for confirming sleeplessness; however, it is generally not used for this purpose because it may be inaccurate in insomnia patients who lie awake without moving. Its primary use is to confirm sleep log data.",
"     </li>",
"     <li>",
"      Other tests &ndash; Other diagnostic tests should be considered as indicated by the clinical evaluation. As examples, echocardiography, thyroid function tests, blood glucose and hemoglobin A1C measurements, blood urea nitrogen and creatinine levels, or iron studies may be performed if heart failure, hyperthyroidism, diabetes mellitus, renal disease, or restless legs syndrome is suspected, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311844\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is confirmed when all three of the following criteria are met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41541/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient reports difficulty initiating asleep, difficulty maintaining asleep, waking up too early, chronically nonrestorative sleep, or poor quality sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      These sleep difficulties occur despite adequate opportunity and circumstances for sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient describes daytime impairment that is attributable to the sleep difficulties. This may include fatigue or malaise; attention, concentration, or memory impairment; social dysfunction, vocational dysfunction, or poor school performance; mood disturbance or irritability; daytime sleepiness; motivation, energy, or initiative reduction; errors or accidents at work or while driving; tension, headaches, or gastrointestinal symptoms in response to sleep loss;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concerns or worries about sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When there is evidence that a condition known to be associated with insomnia exists, the patient is considered to have \"insomnia associated with\" the condition. This includes medical conditions, psychiatric disorders, neurologic diseases, sleep disorders, medications, and other substances. As an example, when a patient with insomnia is found to have major depression, the diagnosis of \"insomnia associated with a mental disorder\" is applied.",
"   </p>",
"   <p>",
"    In contrast, insomnia is designated as an independent disorder when a condition, medication, or substance known to be associated with insomnia cannot be identified, or the insomnia continues after the comorbid condition in controlled. Independent insomnia disorders include acute, psychophysiological (ie, primary), idiopathic, paradoxical, and unspecified insomnia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311852\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is often confused with short duration sleep and sleep deprivation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short duration sleep &ndash; Sleep for a short duration can be normal as some individuals simply require less sleep and can sleep fewer hours without daytime complaints. Short duration sleep is distinguished from insomnia by the absence of daytime impairment.",
"     </li>",
"     <li>",
"      Sleep deprivation &ndash; Sleep deprivation and insomnia are both characterized by a short duration of sleep and impaired daytime function; however, sleep deprivation is due to volitional sleep loss or insufficient opportunity to sleep. Sleep deprived individuals will rapidly fall asleep if given the opportunity, which distinguishes them from patients with insomnia who typically feel fatigued during the day, but are unable to fall asleep if given a chance to take a nap.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/16/2306?source=see_link\">",
"       \"Patient information: Insomnia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/24/28035?source=see_link\">",
"       \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insomnia is often a symptom of a medical, psychiatric, sleep, or neurological disorder, or a consequence of an acute stressor, medication, substance, poor sleep habits, or changes in the sleep environment. However, insomnia may be an independent disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with insomnia typically present with complaints of difficulty initiating sleep, difficulty maintaining sleep, waking up too early, chronically nonrestorative sleep, or poor quality sleep. They may also complain of symptoms of insufficient or poor sleep (eg, daytime sleepiness). (See",
"      <a class=\"local\" href=\"#H2311479\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insomnia is a clinical diagnosis. Therefore, a sleep history is the only diagnostic evaluation that is required to confirm or exclude insomnia. Insomnia is confirmed when all three of the following criteria are met: The patient reports difficulty initiating asleep, difficulty maintaining asleep, waking up too early, chronically nonrestorative sleep, or poor quality sleep; these sleep difficulties occur despite adequate opportunity and circumstances for sleep; and, the patient describes daytime impairment that is attributable to the sleep difficulties. (See",
"      <a class=\"local\" href=\"#H2311844\">",
"       'Diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Sleep history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although not required to confirm or exclude insomnia, most patients undergo additional evaluation to determine whether the insomnia is associated with another condition, medication, or substance. The evaluation typically begins with a medical history and physical examination. Additional diagnostic testing is based upon the history and physical examination. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Medical history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insomnia is often confused with a short sleep requirement and sleep deprivation. A short sleep requirement can be distinguished from insomnia because patients with short duration sleep do not have daytime impairment, whereas patients with insomnia do. Sleep deprivation can be distinguished from insomnia because patients with sleep deprivation rapidly fall asleep if given the opportunity, whereas patients with insomnia do not. (See",
"      <a class=\"local\" href=\"#H2311852\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/1\">",
"      Chesson A Jr, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2000; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/2\">",
"      Monk TH, Reynolds CF, Kupfer DJ, et al. The Pittsburgh Sleep Diary. J Sleep Res 1994; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     Hauri P, Linde S. No More Sleepless Nights, John Wiley &amp; Sons, New York 1996.",
"    </li>",
"    <li>",
"     Spielman AJ, Yang C, Glovinsky PB. Assessment techniques for insomnia. In: Principles and practice of sleep medicine, 4th Ed, Kryger M, Roth T, Dement WC (Eds), Saunders, Philadelphia 2005. p.626.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/5\">",
"      Buysse DJ, Ancoli-Israel S, Edinger JD, et al. Recommendations for a standard research assessment of insomnia. Sleep 2006; 29:1155.",
"     </a>",
"    </li>",
"    <li>",
"     International classification of sleep disorders: Diagnostic and coding manual, 2nd ed, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/7\">",
"      Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/8\">",
"      Practice parameters for the use of polysomnography in the evaluation of insomnia. Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1995; 18:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/9\">",
"      Sadeh A, Hauri PJ, Kripke DF, Lavie P. The role of actigraphy in the evaluation of sleep disorders. Sleep 1995; 18:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41541/abstract/10\">",
"      Natale V, Plazzi G, Martoni M. Actigraphy in the assessment of insomnia: a quantitative approach. Sleep 2009; 32:767.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7676 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41541=[""].join("\n");
var outline_f40_36_41541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311471\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2311479\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sleep history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311844\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311852\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7676|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/53/4955\" title=\"figure 1\">",
"      [ARC]Consensus sleep diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/62/14318\" title=\"table 1\">",
"      Consensus sleep diary instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/17/40221\" title=\"table 2\">",
"      Causes of chronic insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38553?source=related_link\">",
"      Comorbid anxiety and depression: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/24/28035?source=related_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7671?source=related_link\">",
"      Sleep apnea and other causes of impaired sleep in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41542="Ertapenem: Drug information";
var content_f40_36_41542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ertapenem: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/41/9876?source=see_link\">",
"    see \"Ertapenem: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/3/20533?source=see_link\">",
"    see \"Ertapenem: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      INVanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Carbapenem",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. therapy may be administered for up to 14 days; I.M. for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):",
"     </b>",
"     I.M., I.V.: 1 g daily; duration of total antibiotic treatment: 10-14 days; duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.",
"     <b>",
"      Note:",
"     </b>",
"     The carbapenems, including ertapenem, are preferred agents for",
"     <i>",
"      Enterobacter",
"     </i>",
"     spp and",
"     <i>",
"      Burkholderia pseudomallei,",
"     </i>",
"     and are considered alternative agents for anaerobes in aspiration pneumonia (IDSA, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection:",
"     </b>",
"     I.M., I.V.: 1 g daily for 5-14 days;",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend a treatment duration of 4-7 days (provided source controlled) for community-acquired, mild-to-moderate IAI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic infections (acute):",
"     </b>",
"     I.M., I.V.: 1 g daily for 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of surgical site following colorectal surgery:",
"     </b>",
"     I.V.: 1 g given 1 hour preoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Skin and skin structure infections (excluding diabetic foot infections with osteomyelitis):",
"     </b>",
"     I.M., I.V.: 1 g daily for 7-14 days.",
"     <b>",
"      Notes:",
"     </b>",
"     For diabetic foot infections, recommended treatment duration is up to 4 weeks depending on severity of infection and response to therapy (Lipsky, 2012); guidelines recommend ertapenem as a preferred agent for animal bites. (IDSA, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intravenous catheter-related bloodstream infection (unlabeled use):",
"     </b>",
"     I.V. 1 g daily (",
"     <b>",
"      Note:",
"     </b>",
"     Carbapenems, including ertapenem, are preferred agents for extended-spectrum &beta;-lactamase (ESBL)-positive",
"     <i>",
"      Escherichia coli",
"     </i>",
"     and",
"     <i>",
"      Klebsiella, Enterobacter,",
"     </i>",
"     and",
"     <i>",
"      Serratia",
"     </i>",
"     [IDSA, 2009].)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection:",
"      <b>",
"       <i>",
"        Enterobacter",
"       </i>",
"      </b>",
"      spp (unlabeled use)",
"     </b>",
"     : I.V.: 1 g every 24 hours for 4-6 weeks (Osmon, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F166549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/3/20533?source=see_link\">",
"      see \"Ertapenem: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. therapy may be administered for up to 14 days; I.M. therapy for up to 7 days",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Children 3 months to 12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):",
"     </b>",
"     I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g daily); duration of total antibiotic treatment: 10-14 days (",
"     <b>",
"      Note:",
"     </b>",
"     Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection:",
"     </b>",
"     I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g daily) for 5-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pelvic infections (acute):",
"     </b>",
"     I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g daily) for 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g daily) for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;13 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Community-acquired pneumonia, complicated urinary tract infections (including pyelonephritis):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intra-abdominal infection:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pelvic infections (acute):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure infections (excluding diabetic foot infections with osteomyelitis):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F166539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: No data available for pediatric patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and ESRD: 500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: When the daily dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is required following hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CAPD: I.V.: 500 mg daily (Cardone, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F166540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjustments cannot be recommended (lack of experience and research in this patient population).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INVanz&reg;: 1 g [contains sodium ~137 mg (~6 mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Avoid injection into a blood vessel. Make sure patient does not have an allergy to lidocaine or another anesthetic of the amide type. Administer by deep I.M. injection into a large muscle mass (eg, gluteal muscle or lateral part of the thigh). Do not administer I.M. preparation or drug reconstituted for I.M. administration intravenously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F166563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; per manufacturer do",
"     <b>",
"      not",
"     </b>",
"     mix with other medications or use diluents containing dextrose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Daptomycin, heparin, hetastarch in NS, potassium chloride, telavancin, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Anidulafungin, caspofungin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the following moderate-to-severe infections: Complicated intra-abdominal infections, complicated skin and skin structure infections (including diabetic foot infections without osteomyelitis, animal and human bites), complicated UTI (including pyelonephritis), acute pelvic infections (including postpartum endomyometritis, septic abortion, postsurgical gynecologic infections), and community-acquired pneumonia. Prophylaxis of surgical site infection following elective colorectal surgery. Antibacterial coverage includes aerobic gram-positive organisms, aerobic gram-negative organisms, and anaerobic organisms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Methicillin-resistant",
"     <i>",
"      Staphylococcus aureus, Enterococcus",
"     </i>",
"     spp, penicillin-resistant strains of",
"     <i>",
"      Streptococcus pneumoniae,",
"     </i>",
"     <i>",
"      Acinetobacter",
"     </i>",
"     , and",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ,  are",
"     <b>",
"      resistant",
"     </b>",
"     to ertapenem while most extended-spectrum &beta;-lactamase (ESBL)-producing bacteria remain sensitive to ertapenem.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13471083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of intravenous catheter-related bloodstream infection; treatment of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ertapenem may be confused with doripenem, imipenem, meropenem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       INVanz&reg; may be confused with AVINza&reg;, I.V. vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3%), chest pain (1% to 2%), hypertension (1% to 2%), hypotension (1% to 2%), tachycardia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 7%); altered mental status (eg, agitation, confusion, disorientation, mental acuity decreased, somnolence, stupor) (3% to 5%); fever (2% to 5%), insomnia (3%), dizziness (2%), hypothermia (infants, children, and adolescents &lt;2%), fatigue (1%), anxiety (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Diaper rash (infants and children 5%), rash (2% to 3%), pruritus (1% to 2%), erythema (1% to 2%), genital rash (infants, children, and adolescents &lt;2%), skin lesions (infants, children, and adolescents &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (2%), hyperglycemia (1% to 2%), hyperkalemia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (2% to 10%), nausea (6% to 9%), abdominal pain (4% to 5%), constipation (2% to 4%), acid regurgitation (1% to 2%), appetite decreased (infants, children, and adolescents &lt;2%), dyspepsia (1%), oral candidiasis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urine WBCs increased (2% to 3%), urine RBCs increased (1% to 3%), vaginitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytosis (4% to 7%), hematocrit/hemoglobin decreased (3% to 5%), eosinophils increased (1% to 2%), leukopenia (1% to 2%), neutrophils decreased (1% to 2%), thrombocytopenia (1%), prothrombin time increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic enzyme increased (7% to 9%), alkaline phosphatase increase (4% to 7%), albumin decreased (1% to 2%), bilirubin (total) increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infused vein complications (5% to 7%), phlebitis/thrombophlebitis (2%), extravasation (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents &lt;2%), weakness (1%), leg pain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (infants, children, and adolescents &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 4%), dyspnea (1% to 3%), nasopharyngitis (infants, children, and adolescents &lt;2%), rhinitis (infants, children, and adolescents &lt;2%), rhinorrhea (infants, children, and adolescents &lt;2%), upper respiratory tract infection (infants, children, and adolescents &lt;2%), wheezing (infants, children, and adolescents &lt;2%), pharyngitis (1%), rales/rhonchi (1%), respiratory distress (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes simplex (infants, children, and adolescents &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reactions, anaphylaxis, arrhythmia, asthma, asystole, atrial fibrillation, bradycardia, bronchoconstriction,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea, cardiac arrest, cholelithiasis, delirium, DRESS syndrome, gastrointestinal hemorrhage, gout, heart failure, heart murmur, hemoptysis, hypoxemia, ileus, jaundice, oliguria/anuria, pancreatitis, pleural effusion, renal insufficiency, seizure, septicemia, septic shock, subdural hemorrhage, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ertapenem, other carbapenems (eg, doripenem, imipenem, meropenem), or any component of the formulation; anaphylactic reactions to beta-lactam antibiotics. If using intramuscularly, known hypersensitivity to local anesthetics of the amide type (lidocaine is the diluent).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction. Increased seizure risk has been reported in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid and derivatives:  Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Lower doses (based upon renal function) are often required in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;3 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.M. administration: Doses for I.M. administration are mixed with lidocaine; consult Lidocaine (Systemic) information for associated Warnings/Precautions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ertapenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Ertapenem is approved for the treatment of postpartum endomyometritis, septic abortion, and postsurgical infections. Information related to use during pregnancy has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F166517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ertapenem is excreted in breast milk. The low concentrations in milk and low oral bioavailability suggest minimal exposure risk to the infant. The manufacturer recommends that caution be exercised when administering ertapenem to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F166518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (INVanz Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $84.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (INVanz Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $89.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematopoietic assessment during prolonged therapy; neurological assessment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Invanz (AR, AT, AU, BE, BG, BO, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 3 months to 12 years: ~0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 13-17 years: ~0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adults: ~0.12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent, primarily to albumin): 85% at 300 mcg/mL, 95% at &lt;100 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Non-CYP-mediated hydrolysis to inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 3 months to 12 years: ~2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children &ge;13 years and Adults: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.M.: ~2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~80% as unchanged drug and metabolite); feces (~10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cardone KE, Grabe DW, Kulawy RW, et al, &ldquo;Ertapenem Pharmacokinetics and Pharmacodynamics During Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2011, 56(2):725-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/22083473/pubmed\" id=\"22083473\" target=\"_blank\">",
"        22083473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lunde JL, Nelson RE, and Storandt HF, &ldquo;Acute Seizures in a Patient Receiving Divalproex Sodium After Starting Ertapenem Therapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(8):1202-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/17655519/pubmed\" id=\"17655519\" target=\"_blank\">",
"        17655519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults,&rdquo; 2007,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 44(Suppl 2):27-72",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/17278083/pubmed\" id=\"17278083\" target=\"_blank\">",
"        17278083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(1):1-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/19489710/pubmed\" id=\"19489710\" target=\"_blank\">",
"        19489710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seto AH, Song JC, and Guest SS, &ldquo;Ertapenem-Associated Seizures in a Peritoneal Dialysis Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(2):352-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/15644469/pubmed\" id=\"15644469\" target=\"_blank\">",
"        15644469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(10):1373-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/36/41542/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8675 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41542=[""].join("\n");
var outline_f40_36_41542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166557\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166537\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166549\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166538\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166539\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166540\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166510\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166512\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166563\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166511\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13471083\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166555\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166515\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166500\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299280\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166504\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166506\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166516\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166543\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166517\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166518\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323133\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166508\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869380\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166499\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166514\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8675|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/41/9876?source=related_link\">",
"      Ertapenem: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/3/20533?source=related_link\">",
"      Ertapenem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41543="Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease";
var content_f40_36_41543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Nicholas S Hill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Naomi R Kramer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41543/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/36/41543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive ventilation refers to mechanical ventilation without the need for an invasive interface (ie, an invasive artificial airway) between the ventilatory device and the patient. Noninvasive ventilation is now commonly used to assist ventilation in patients with a variety of chronic neuromuscular and chest wall diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of neuromuscular and chest wall diseases may lead to respiratory compromise and failure. These include spinal cord lesions, motor neuron disease, disorders of the neuromuscular junction, diseases of peripheral nerves, diseases of muscles, and chest wall disorders.",
"   </p>",
"   <p>",
"    The incidence of respiratory muscle dysfunction varies among these different entities. In neuromuscular disease, the degree of compromise may differ significantly between respiratory and nonrespiratory muscles, and not all respiratory muscles may be similarly impaired. The clinical course also varies, as respiratory muscle weakness may be:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Completely reversible (Guillain-Barr&eacute; syndrome)",
"     </li>",
"     <li>",
"      Reversible with treatment (myasthenia gravis)",
"     </li>",
"     <li>",
"      Relapsing (multiple sclerosis)",
"     </li>",
"     <li>",
"      Relentlessly progressive (amyotrophic lateral sclerosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In several of these disease processes, respiratory function may also be compromised by parenchymal lung disease (eg, polymyositis) or abnormal control of breathing (eg, myotonic dystrophy). Nevertheless, despite the diversity of these underlying conditions, the respiratory consequences of severe disease tend to be similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link\">",
"     \"Diseases of the chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal noninvasive ventilation may be delivered by either positive or negative pressure devices. Noninvasive positive pressure ventilation (NPPV) is used for the majority of patients with respiratory insufficiency due to neuromuscular or chest wall disease and is discussed here. Detailed descriptions of the various types of noninvasive ventilation systems and common problems in their clinical use are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43060?source=see_link\">",
"     \"Troubleshooting problems with noninvasive positive pressure ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjective clinical findings and objective physiologic tests are used to determine when nocturnal noninvasive ventilation is indicated in the management of patients with neuromuscular and chest wall disease (",
"    <a class=\"graphic graphic_table graphicRef79358 \" href=\"mobipreview.htm?13/18/13611\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Detailed discussions of patient selection are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3528?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=see_link&amp;anchor=H11#H11\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal noninvasive ventilation is NOT indicated for patients with acute respiratory failure. The role of noninvasive ventilation in acute respiratory failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision is made to initiate noninvasive nocturnal ventilation, certain preparative steps will improve ultimate patient acceptance and success (",
"    <a class=\"graphic graphic_table graphicRef51437 \" href=\"mobipreview.htm?39/37/40539\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72444 \" href=\"mobipreview.htm?42/57/43931\">",
"     table 3",
"    </a>",
"    ). These include appropriate timing of initiation; mask selection and fitting; and selection of ventilator type and initial settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Timing and location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial trial of noninvasive nocturnal ventilatory support can be conducted in an outpatient setting, in a sleep laboratory, or during an overnight admission. To facilitate acceptance, an overnight admission may be most appropriate for patients who are anxious or have more advanced disease.",
"   </p>",
"   <p>",
"    Wherever the initial trial is conducted, a trained provider is needed to work with the patient to select the correct mask size, implement the initial ventilator settings, and then adjust mask fit and ventilator settings to achieve patient comfort. This process usually takes two to four hours.",
"   </p>",
"   <p>",
"    Sometimes, transient NPPV in conjunction with mechanically or manually assisted cough may help stabilize patients with premature decompensation due to intercurrent respiratory infection or other respiratory illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Masks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard nasal continuous positive airway pressure (CPAP) masks are generally preferred for chronic applications, while oronasal masks are usually preferred for acute indications. Nasal pillows may be preferred by patients with ALS who are able to maintain a mouth seal; oronasal masks may be preferred by habitual mouth breathers who may find them more comfortable. However, quick release straps and close caregiver supervision are necessary in patients with significant upper extremity weakness who have difficulty removing the mask independently.",
"   </p>",
"   <p>",
"    Templates are available (Respironics, Inc) to assist with mask sizing. In general, the smallest mask that fits comfortably should be selected. A more detailed description of types of masks is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link&amp;anchor=H3#H3\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\", section on 'Interfaces'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important aspect of mask fitting is setting the strap tension. A looser strap tension helps to protect the skin from irritation and breakdown, but this must be balanced against air leaks due to a loose fit. Generally, the least amount of strap tension that does not allow a leak is used. Some patients may need a chin strap to prevent air leakage from the mouth. If this is unsuccessful, an oronasal mask may need to be substituted.",
"   </p>",
"   <p>",
"    If the cheek or neck becomes irritated by the strap edges, soft cloth strips of fleece or cotton may be placed under the straps to help protect the skin. Washing the face prior to placing the mask may help to decrease skin irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ventilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) is now considered the mode of choice among noninvasive ventilators for reasons of convenience, portability, and efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/4\">",
"     4",
"    </a>",
"    ]. Other types of noninvasive ventilators are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link&amp;anchor=H4#H4\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\", section on 'Ventilators'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either pressure or volume-cycled ventilators may be used to deliver NPPV. The ventilatory mode used by pressure-cycled ventilators is also known as bilevel positive airway pressure (BPAP). It delivers both a preset inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The assist-control mode is used for volume-cycled ventilators.",
"   </p>",
"   <p>",
"    Evidence to guide ventilator selection is lacking, so the choice is usually based on practitioner experience and preference. However, pressure-cycled ventilators may be preferred due to lower cost. Regardless of whether a volume or pressure-cycled device is used, the initial priority should be to achieve patient comfort rather than any particular level of improvement in gas exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of initial settings is to provide a modest amount of ventilatory support, while allowing the patient to become acclimated to NPPV (",
"    <a class=\"graphic graphic_table graphicRef51437 \" href=\"mobipreview.htm?39/37/40539\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72444 \" href=\"mobipreview.htm?42/57/43931\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tolerance of bilevel positive airway pressure devices is facilitated by using",
"    <strong>",
"     low initial pressures",
"    </strong>",
"    . Initial inspiratory positive airway pressure (IPAP) is typically 8 to 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and expiratory positive airway pressure (EPAP) 4 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, (thus providing inspiratory pressure support [IPAP minus EPAP] of approximately 4 to 6 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O).",
"   </p>",
"   <p>",
"    Initial tidal volumes of 6 to 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    are employed when using a volume-cycled ventilator, starting at the low end of the range and increasing, as needed. These volumes are higher than those commonly used for invasive ventilation, because of the frequent need to compensate for air leaks during noninvasive ventilation. Positive-end expiratory pressure (PEEP) is usually provided at 4 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O; slightly higher PEEP levels may be needed for patients with concomitant COPD.",
"   </p>",
"   <p>",
"    A backup respiratory rate is usually provided for both pressure and volume-cycled ventilators, usually 2 to 4 breaths per minute below the patient's spontaneous rate.",
"   </p>",
"   <p>",
"    Some patients with neuromuscular disease have concomitant obstructive sleep apnea (OSA, a disorder characterized by obstructive apnea and hypopnea) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/5\">",
"     5",
"    </a>",
"    ]. In this setting, a slightly higher expiratory pressure (EPAP) may be required to overcome airway obstruction. In order to provide ventilatory support, the pressure difference between inspiratory and expiratory pressures (IPAP minus EPAP) would need to be maintained (ie, the IPAP would also need to be increased). To determine the optimal expiratory pressure for the OSA and the necessary inspiratory pressure support (difference between inspiratory and expiratory pressures) for hypoventilation, additional polysomnographic examination is needed. Polysomnographic titration should aim not only to eliminate apneas, hypopneas, and respiratory related arousals, but also to augment ventilation in patients with chronic hypoventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initial pressures or volumes have been set, the mask and straps are readjusted as needed to reduce leakage of air from the mask, using as little strap tension as possible. The patient is encouraged to relax and \"let the ventilator do the breathing.\" Sometimes initiation during the daytime using a diversion such as watching television is helpful to facilitate adaptation. A low dose of benzodiazepine may help ease the initial transition to NPPV; however, this should be avoided in patients with hypercapnia.",
"   </p>",
"   <p>",
"    If the patient is very claustrophobic, it may be helpful for them to hold the mask on their face for a few minutes rather than using the straps right away. This allows the patient to remove and reapply the mask quickly during those first few minutes and gives the patient a sense of control. Once the patient can tolerate the mask, the straps will need to be attached for effective ventilation.",
"   </p>",
"   <p>",
"    For those being started as an outpatient, noninvasive ventilation is continued for an additional one to two hours. For those who are staying overnight in the hospital or in a sleep lab that has special expertise in noninvasive ventilation, NPPV can be continued as long as the patient can tolerate it through the night. During this additional time, further adjustments are made to optimize comfort and provide patient and family education, before the patient is discharged to use NPPV at home. However, a small randomized trial found no advantage of initiation during a few days&rsquo; hospitalization compared to initiation at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011 NPPV Titration Task Force of the American Academy of Sleep Medicine recommends initial titration of pressures in a sleep lab to optimize pressure settings in addition to comfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/7\">",
"     7",
"    </a>",
"    ]. It is believed that titration in the lab with careful analysis of effort and flow may help to mitigate patient-ventilator asynchrony that may occur when patients are initially placed on NPPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this recommendation is based on expert opinion and evidence is lacking to demonstrate the superiority of this approach over home initiation. Thus, if in-lab polysomnography is not readily available or the lab lacks the appropriate experience, then initiation of NPPV should not be delayed while waiting for a study. The adaption process described below may be initiated in the outpatient setting, and the patient may subsequently be evaluated in the lab if problems are encountered. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Adaptation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An arterial blood gas at the end of the trial is useful to gauge the augmentation of ventilatory assistance. To prevent an acute alkalosis, we generally aim for an overnight decrease in PaCO",
"    <sub>",
"     2",
"    </sub>",
"    of 8 mmHg (1.06 kPa) or less. Noninvasive measurements, such as oxygen saturation, may also be useful to monitor gas exchange in patients with restrictive thoracic disorders and normal lungs. During administration of NPPV, end-tidal PCO",
"    <sub>",
"     2",
"    </sub>",
"    measurements via the mask may underestimate actual PaCO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    Upward adjustments are made in inspiratory pressures or tidal volumes as indicated by symptoms, gas exchange, and patient tolerance. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Adaptation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Humidification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal saline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heated humidification enhance comfort by decreasing dryness in the upper airway. However, it is important to avoid excess heating that may lead to water condensation, also called \"rainout\", in the tubing or mask; reducing the temperature setting of the heated humidifier may help reduce rainout. If condensation is still noted, the tubing may be insulated with light weight cloth or insulation material that is commercially made for CPAP tubing or created by the patient or family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADAPTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adaptation phase (ie, the first few weeks after initiation) poses the greatest challenge in gaining patient acceptance of noninvasive ventilation. Initially, patients are encouraged to use the device for an hour or two during the daytime, distracting themselves by watching television or reading. When comfortable with the mask, they are instructed to use the noninvasive ventilator each night for at least a few hours, or as long as possible.",
"   </p>",
"   <p>",
"    With NPPV, patients often have trouble adapting to sleeping with an unfamiliar object strapped to their face. Hospitalization may help the particularly anxious patient or those who are medically less stable, but it is unnecessary for success in most patients.",
"   </p>",
"   <p>",
"    Adjustments are often necessary in strap tension, types of straps used, and mask sizes and types, after the patient has returned home. An experienced home respiratory therapist who is willing to experiment with these adjustments can be very helpful. Adjustment of the inspiratory time or trigger sensitivity may also help to improve patient tolerance of NPPV.",
"   </p>",
"   <p>",
"    An important aspect of adaptation is to provide pressures that are sufficient to assist ventilation. Once the patient has begun using the device nocturnally and has been able to fall asleep, the inspiratory pressure is increased to control symptoms of CO",
"    <sub>",
"     2",
"    </sub>",
"    retention (morning headache and daytime hypersomnolence) and to reverse hypoventilation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Increases in pressure are made gradually as tolerated at increments of perhaps 2 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O per week. The larger the difference between inspiratory and expiratory pressure, the greater the inspiratory support provided to assist ventilation. This difference is usually at least 8 to 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, and may range up to 20 or more cm H",
"    <sub>",
"     2",
"    </sub>",
"    O in patients with high inspiratory impedance due to scoliosis or obesity.",
"   </p>",
"   <p>",
"    Patients encountering difficulty adapting are encouraged but never forced to persist. Most patients are able to sleep through the night successfully after weeks to months. Adaptation often succeeds when patients first notice symptomatic improvement. However, perhaps 5 to 10 percent of patients fail to adapt successfully to NPPV, usually because of mask discomfort or claustrophobia. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Failure of nocturnal NPPV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sleep aids like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    are rarely used to help acclimatization to NPPV; they should be avoided in patients with baseline CO",
"    <sub>",
"     2",
"    </sub>",
"    retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial monitoring should focus on patient acceptance of the device, number of hours of use, problems encountered, and symptoms of hypoventilation. Patients should be seen initially every few weeks for assessment of symptoms such as morning headache and hypersomnolence, and for measurement of vital signs and daytime arterial blood gases. It is unrealistic to expect improvements in symptoms or gas exchange until the patient is using the device at least four to five hours nightly, so initial monitoring of gas exchange is performed primarily to assure stability.",
"   </p>",
"   <p>",
"    Improvements in symptoms and gas exchange should be anticipated once the patient has successfully adapted and is sleeping through most of the night while using the device. Daytime heart rate often slows when noninvasive ventilation has been successful.",
"   </p>",
"   <p>",
"    Pulse oximetry and end-tidal PCO",
"    <sub>",
"     2",
"    </sub>",
"    measurements may be helpful in assessing trends; however, end-tidal CO",
"    <sub>",
"     2",
"    </sub>",
"    must be measured off the ventilator because of inaccurate readings of gas sampled via the mask [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/9\">",
"     9",
"    </a>",
"    ]. Noninvasive measurement of PCO",
"    <sub>",
"     2",
"    </sub>",
"    is not sufficiently accurate to replace occasional blood gases.",
"   </p>",
"   <p>",
"    The aim of chronic noninvasive ventilation should be to lower and stabilize daytime arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    ; improve sleep quality and oxygenation; and ameliorate daytime symptoms. The optimal daytime arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    is not known and probably varies among patients. We have observed that patients tolerate daytime spontaneous PCO",
"    <sub>",
"     2",
"    </sub>",
"    levels from 45 to 60 mmHg (5.99 to 7.98 kPa) without cor pulmonale, requirement for O",
"    <sub>",
"     2",
"    </sub>",
"    supplementation, or worsening of hypoventilation symptoms.",
"   </p>",
"   <p>",
"    Once the patient is using the device for at least several hours out of every 24 hour cycle, a nocturnal study during noninvasive ventilation may be useful. Overnight pulse oximetry assesses adequacy of gas exchange and determines whether O",
"    <sub>",
"     2",
"    </sub>",
"    supplementation is indicated. If the patient encounters difficulty adapting or the overnight oximetry shows desaturations, overnight polysomnography may be obtained, particularly for patients in whom the clinician has a high clinical suspicion of OSA. Patients with difficulty using the device nocturnally can still achieve gas exchange benefits by daytime use.",
"   </p>",
"   <p>",
"    If symptoms and daytime PaCO",
"    <sub>",
"     2",
"    </sub>",
"    are well-controlled and nocturnal oximetry shows no desaturation, further adjustments in inspiratory pressure can be made for optimization. Once stabilized, patients can be seen at six monthly intervals, with arterial blood gases and nocturnal oximetry repeated as clinically indicated. Serum bicarbonate can be followed as an indicator of PaCO",
"    <sub>",
"     2",
"    </sub>",
"    and arterial blood gases repeated to confirm any upward trends.",
"   </p>",
"   <p>",
"    If symptoms and gas exchange fail to improve with NPPV, multichannel portable recorders may be helpful to identify the problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/10\">",
"     10",
"    </a>",
"    ]. These devices are used at home to monitor the electrocardiogram, oximetry, chest wall motion, and also airflow at the nose or mask pressure; they may detect excessive air leaking or persistent obstructive apneas. Most positive pressure units also have compliance measures that can document how many hours the patient is using the device. This is occasionally helpful as patients may not correctly estimate their duration of use.",
"   </p>",
"   <p>",
"    Full nocturnal polysomnography may be useful in patients who fail to improve or who deteriorate after prior stabilization, particularly when home monitoring has been unhelpful. In addition to detection of sleep apnea and hypoventilation, these studies allow sleep staging and detection of arousals that are associated with ineffective inspiratory effort (patient effort that does not trigger the ventilator), asynchrony, air leaking through the mouth or around the mask, and other factors that may contribute to a less than optimal symptom resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POTENTIAL BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of nocturnal noninvasive ventilatory support include improvements in survival, daytime gas exchange, and quality of life. These have been evaluated in one randomized study and several case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 41 patients with respiratory insufficiency due to ALS were randomly assigned to either NPPV or no nocturnal ventilatory support [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/13\">",
"       13",
"      </a>",
"      ]. NPPV improved survival by 205 days in patients without bulbar involvement, while no survival benefit was noted in those with bulbar disease. All patients had some improvement in quality of life measures.",
"     </li>",
"     <li>",
"      In a series of 71 patients with ALS offered NPPV when clinically appropriate, independent predictors of improved survival were tolerance of nocturnal NPPV (risk ratio of 0.32, 95% CI: 0.13 to 0.78) and a slower rate of decline of FVC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients with milder bulbar symptoms were more likely to be tolerant of NPPV.",
"     </li>",
"     <li>",
"      A non-randomized study of 244 patients with kyphoscoliosis reported improved survival with home noninvasive mechanical ventilation compared to long-term oxygen therapy (hazard ratio of 0.30 [95% CI of 0.18 to 0.51]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact mechanism by which nocturnal noninvasive ventilation can correct daytime hypoventilation in patients with neuromuscular and chest wall disease has not been fully elucidated. It is hypothesized that central chemoreceptor sensitivity may be restored by correction of profound nocturnal hypercapnia, or that the quality of sleep is changed when nocturnal noninvasive ventilation is employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FAILURE OF NOCTURNAL NPPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a period of stabilization on nocturnal NPPV, some patients have deterioration of daytime gas exchange and symptoms related to progression of their underlying disease. Stability in these patients may be restored by adding daytime naps and extending the total duration of NPPV per 24 hour period. In addition, various combinations of noninvasive ventilatory support, manually assisted coughing, and glossopharyngeal breathing may be used to promote clearance of secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/15,21,22\">",
"     15,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of other problems may develop during long-term nocturnal NPPV, including mask intolerance, airway dryness, nasal skin irritation, and gastric air insufflation. An approach to resolving these complications is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43060?source=see_link\">",
"     \"Troubleshooting problems with noninvasive positive pressure ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INVASIVE VENTILATORY SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients whose respiratory insufficiency is not adequately addressed by noninvasive ventilation, the decision to switch from noninvasive to invasive ventilation depends in large part upon patient preference. Some patients are reluctant or flatly refuse to consider invasive ventilation. Most prefer to continue noninvasive ventilation as long as possible.",
"   </p>",
"   <p>",
"    For patients who will accept short or long-term invasive ventilation, the clearest indications are failure to maintain adequate oxygenation, acute respiratory acidosis, and the inability to adequately protect the upper airway, due to impaired swallowing or cough, excessive secretions, or a combination of these factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of invasive ventilation may be temporary if inability to protect the airway is related to an infection-induced increase in secretions. Noninvasive ventilatory assistance may be resumed when the secretions subside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECT ON CAREGIVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited information is available about the impact of NPPV on caregivers of patients with neuromuscular and chest wall diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41543/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As patients survive longer with NPPV, caregiver stress appears to increase due to a greater duration of progressive illness. This does not mean that NPPV should not be instituted, but rather that adequate support and training for caregivers should be an important part of the overall care provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive ventilation (ie, ventilation without an invasive artificial airway) is now used commonly to assist ventilation in patients with a variety of chronic neuromuscular and chest wall diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential recipients of noninvasive ventilation should be selected using established guidelines (",
"      <a class=\"graphic graphic_table graphicRef79358 \" href=\"mobipreview.htm?13/18/13611\">",
"       table 1",
"      </a>",
"      ). Polysomnography may be included in the evaluation to assess for concomitant obstructive sleep apnea (OSA), but is not necessary for noninvasive ventilation to qualify for reimbursement. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with neuromuscular or chest wall disease who require nocturnal ventilatory support, noninvasive positive pressure ventilation (NPPV) is generally preferred over other types of noninvasive ventilators for reasons of convenience, portability, and efficacy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard nasal (CPAP) or nasal pillow masks are usually preferred for chronic applications, while oronasal masks are preferred for acute indications. Patients experiencing excessive air leaking through the mouth with nasal interfaces may benefit from using a chin strap with the nasal interface or changing to an oronasal mask. Less commonly, patients will prefer use of a mouthpiece interface. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Masks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either a pressure or a volume-cycled ventilator may be used to deliver NPPV (",
"      <a class=\"graphic graphic_table graphicRef51437 \" href=\"mobipreview.htm?39/37/40539\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72444 \" href=\"mobipreview.htm?42/57/43931\">",
"       table 3",
"      </a>",
"      ). When using a bilevel positive airway pressure device, we select low initial pressures to improve patient tolerance. For example, initial inspiratory positive airway pressure (IPAP) is typically 8 to 10 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O and expiratory positive airway pressure (EPAP) typically 4 to 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. When using a volume-cycled ventilator, we select assist-control mode with initial tidal volumes in the range of 6 to 10",
"      <span class=\"nowrap\">",
"       mL/kg,",
"      </span>",
"      starting at the low end of the range and increasing, as needed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the initial pressures or volumes have been set, the mask and straps are readjusted as needed to reduce leakage of air from the mask, using as little strap tension as possible; some patients using a nasal mask may need a chin strap to control oral air leakage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adjustments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initiating nocturnal NPPV, inspiratory pressure or tidal volume are gradually adjusted upward to lower and stabilize daytime arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ); improve sleep quality and oxygenation; and ameliorate daytime symptoms. Overnight pulse oximetry assesses adequacy of gas exchange and determines whether O",
"      <sub>",
"       2",
"      </sub>",
"      supplementation is indicated. The optimal daytime PaCO",
"      <sub>",
"       2",
"      </sub>",
"      is not known and probably varies among patients, although patients seem to tolerate daytime spontaneous PaCO",
"      <sub>",
"       2",
"      </sub>",
"      levels from 45 to 60 mmHg (5.99 to 7.98 kPa). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polysomnography may be helpful in the evaluation of patients who are not improving with NPPV or are having difficulty tolerating it. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nocturnal hypoventilation caused by neuromuscular or chest wall disease, nocturnal NPPV may improve survival and quality of life. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Potential benefits'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/1\">",
"      Ozsancak A, D'Ambrosio C, Hill NS. Nocturnal noninvasive ventilation. Chest 2008; 133:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/2\">",
"      Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med 1994; 120:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/3\">",
"      Bach, JR, Brougher, P, Hess, DR, et al. Consensus statement: Noninvasive positive pressure ventilation. Respir Care 1997; 42:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/4\">",
"      Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/5\">",
"      Dhand UK, Dhand R. Sleep disorders in neuromuscular diseases. Curr Opin Pulm Med 2006; 12:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/6\">",
"      Chatwin M, Nickol AH, Morrell MJ, et al. Randomised trial of inpatient versus outpatient initiation of home mechanical ventilation in patients with nocturnal hypoventilation. Respir Med 2008; 102:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/7\">",
"      Berry RB, Chediak A, Brown LK, et al. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 2010; 6:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/8\">",
"      Atkeson AD, RoyChoudhury A, Harrington-Moroney G, et al. Patient-ventilator asynchrony with nocturnal noninvasive ventilation in ALS. Neurology 2011; 77:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/9\">",
"      Sanders MH, Kern NB, Costantino JP, et al. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. Chest 1994; 106:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/10\">",
"      Janssens JP, Borel JC, P&eacute;pin JL, SomnoNIV Group. Nocturnal monitoring of home non-invasive ventilation: the contribution of simple tools such as pulse oximetry, capnography, built-in ventilator software and autonomic markers of sleep fragmentation. Thorax 2011; 66:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/11\">",
"      Fanfulla F, Delmastro M, Berardinelli A, et al. Effects of different ventilator settings on sleep and inspiratory effort in patients with neuromuscular disease. Am J Respir Crit Care Med 2005; 172:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/12\">",
"      Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997; 127:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/13\">",
"      Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/14\">",
"      Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 2006; 67:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/15\">",
"      Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS. Chest 2002; 122:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/16\">",
"      Windisch W, Quality of life in home mechanical ventilation study group. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/17\">",
"      Tsolaki V, Pastaka C, Kostikas K, et al. Noninvasive ventilation in chronic respiratory failure: effects on quality of life. Respiration 2011; 81:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/18\">",
"      Gustafson T, Franklin KA, Midgren B, et al. Survival of patients with kyphoscoliosis receiving mechanical ventilation or oxygen at home. Chest 2006; 130:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/19\">",
"      Annane D, Quera-Salva MA, Lofaso F, et al. Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases. Eur Respir J 1999; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/20\">",
"      Turkington PM, Elliott MW. Rationale for the use of non-invasive ventilation in chronic ventilatory failure. Thorax 2000; 55:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/21\">",
"      Bach JR. Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory aids. Chest 1994; 105:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/22\">",
"      Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care 2006; 51:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/23\">",
"      Sundling, I-M, Ekman, S-L, Weinberg, J, Klefbeck, B. Patients' with ALS and Caregivers' experiences of non-invasive home ventilation. Adv Physiother 2007; 99999:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41543/abstract/24\">",
"      Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006; 66:1211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5118 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41543=[""].join("\n");
var outline_f40_36_41543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Timing and location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Masks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ventilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjustments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Humidification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADAPTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POTENTIAL BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FAILURE OF NOCTURNAL NPPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INVASIVE VENTILATORY SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECT ON CAREGIVERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/5118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/18/13611\" title=\"table 1\">",
"      Patient selection for noninvasive ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/37/40539\" title=\"table 2\">",
"      Initiation of pressure-cycled NPPV in NM disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/57/43931\" title=\"table 3\">",
"      Initiation of volume-cycled NPPV in NM disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3528?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43060?source=related_link\">",
"      Troubleshooting problems with noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41544="Transient hypogammaglobulinemia of infancy";
var content_f40_36_41544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transient hypogammaglobulinemia of infancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Ilan Dalal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Chaim M Roifman, MD, FRCPC, FCACB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41544/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/36/41544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1956, Gitlin and Janeway published their classic report, \"Agammaglobulinemia: Congenital, Acquired and Transient Forms\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/1\">",
"     1",
"    </a>",
"    ]. This was the first clinical description of a",
"    <strong>",
"     T",
"    </strong>",
"    ransient form of",
"    <strong>",
"     H",
"    </strong>",
"    ypogammaglobulinemia of",
"    <strong>",
"     I",
"    </strong>",
"    nfancy (THI). Despite this discovery decades ago and the significant progress in understanding the pathogenesis of other forms of humoral immunodeficiency, very little is currently known about THI.",
"   </p>",
"   <p>",
"    Clinicians must have the appropriate tools to accurately diagnose THI and the ability to distinguish the disorder from other types of immunodeficiency. Early accurate diagnosis and effective treatment may prevent devastating consequences.",
"   </p>",
"   <p>",
"    This topic review summarizes the characteristics of THI, including definition, possible etiology(ies), clinical manifestations, treatment, and prognosis. An overview of primary humoral deficiencies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULIN LEVELS IN INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum immunoglobulin levels in infancy vary based upon the maturity of the newborn, placental transfer of maternal immunoglobulin, time since birth, and ability of the infant to produce immunoglobulin (",
"    <a class=\"graphic graphic_table graphicRef50967 \" href=\"mobipreview.htm?6/48/6925\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73913 \" href=\"mobipreview.htm?31/25/32157\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunoglobulin G",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, most serum immunoglobulin (Ig) G is derived from the transfer of maternal IgG across the placenta during the third trimester of pregnancy. As a result, serum IgG levels at birth are commonly equal to or slightly higher than maternal serum IgG levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/2\">",
"     2",
"    </a>",
"    ], and premature infants have lower IgG concentrations than full-term infants. Premature infants of 30 to 32 weeks gestation have cord IgG concentrations of approximately 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/3\">",
"     3",
"    </a>",
"    ]. Small for gestational age (SGA) neonates may also have somewhat lower IgG levels than full-term neonates, reflecting possible impaired placental transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After birth, levels of maternally derived IgG rapidly decline, reaching a nadir of approximately 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at three to six months. At the same time, the infant's own production of IgG is not fully developed. This sequence of events represents normal '",
"    <strong>",
"     physiologic",
"    </strong>",
"    ' hypogammaglobulinemia.",
"   </p>",
"   <p>",
"    This phenomenon is more pronounced in premature infants. One study, for example, reported concentrations of 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at three months of age in premature infants born at 25 to 28 and 29 to 30 weeks gestation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/6\">",
"     6",
"    </a>",
"    ]. Most did not have an increased incidence of infections despite these very low IgG concentrations. By the age of one year, the total IgG concentration is normally approximately 60 percent of adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     IgG subclasses",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG has four distinct subclasses that differ in structure and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. IgG1 fixes complement better than IgG2 and IgG3, while IgG4 does not bind C1q and therefore does not fix complement. IgG1 and IgG3 bind Fc receptors at higher affinity than IgG2 or IgG4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/5,8-15\">",
"     5,8-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The IgG2 subclass contains predominantly antibodies directed against polysaccharide antigens, and it was intuitively postulated that low IgG2 levels would predispose individuals to infections with polysaccharide-encapsulated bacteria. While many reports initially supported this notion, some studies have challenged it. Asymptomatic individuals with reduced IgG2, but normal responses to polysaccharide antigens were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/16\">",
"     16",
"    </a>",
"    ]. Further, patients with recurrent bacterial infections and a reduced ability to produce polysaccharide antibodies despite normal IgG subclasses have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus the significance of low IgG2 levels in children and its natural history remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study of 13 children with IgG2 deficiencies, four of whom had previously had THI, found that all 13 cases resolved spontaneously, over periods of several months to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, in most cases IgG2 subclass deficiency may reflect an exaggeration of an already existing maturational delay in subclass maturation and may represent the last stage in resolution of transient hypogammaglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other Ig isotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA, IgM, IgD, and IgE are not placentally transferred under normal circumstances. The presence of elevated levels of IgM or IgA in cord blood may actually suggest an intrauterine infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following represent the normal change in serum IgM and IgA concentrations after birth:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgM concentration rises rapidly for the first month after birth, presumably in response to the massive antigenic stimulation of the new environment. It then increases more gradually to a level that is approximately 60 percent of an adult's level by the age of one year.",
"     </li>",
"     <li>",
"      IgA concentrations rise slower than IgM, up to values of only 20 percent of those of adults by one year of age. It subsequently continues to rise progressively through adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;THI has been classically defined as an accentuation and prolongation of the 'physiologic' hypogammaglobulinemia of infancy, which is normally observed during the first three to six months of life. Nevertheless, the criteria for the diagnosis are not well standardized.",
"   </p>",
"   <p>",
"    In 1992, the World Health Organization included diminished levels of both IgG and IgA in defining criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/22\">",
"     22",
"    </a>",
"    ], while the latest published report required that one or more classes of Ig may be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/23\">",
"     23",
"    </a>",
"    ]. Most reports have used low IgG levels as a mandatory inclusion criterion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], but others have utilized other immunoglobulin classes, such as low IgA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, IgA levels are an unreliable diagnostic determinant, as levels reach only 20 percent of adult values at one year of age, and there is high variability in the normal range. Although most published studies require that the concentration of at least one class of Ig be more than two standard deviations (SD) below the mean for age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24-27\">",
"     24-27",
"    </a>",
"    ], others have used three SD for the definition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommended diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of THI should be based on the presence of IgG levels",
"    <strong>",
"     at least 2 SD",
"    </strong>",
"    <strong>",
"     below",
"    </strong>",
"    the mean for aged-matched controls as an invariant criteria, with or without diminished values of other Ig isotypes, that persists beyond six months of age and occurs in the absence of other immunodeficiency conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause(s) of THI remains unknown despite a large body of research suggesting numerous pathogenic mechanisms. To a large degree, the following hypotheses reflect the last 40 years in the field of immunology, starting with alloantibodies in the early 1960s and marching into the new millennium with the cytokine imbalance network.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated that gamma globulin (Gm) antigenic determinants, which are present on human fetal IgG molecules but not in the mother, can induce the synthesis of maternal IgG anti-Gm antibodies during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/30\">",
"       30",
"      </a>",
"      ]. The authors concluded that such alloantibodies may cross the placenta and cause transient suppression of fetal immunoglobulin production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/30\">",
"       30",
"      </a>",
"      ]. However, the results of a prospective study failed to support this hypothesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Based upon the finding of THI in relatives of patients with a variety of immune deficiency disorders, some hypothesized the disorder is because of genetic heterozygosity for different immune deficient diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/32\">",
"       32",
"      </a>",
"      ]. However, this seems implausible as it is unclear how a variety of immune system defects would manifest clinically as THI because of a single genetic heterozygosity.",
"     </li>",
"     <li>",
"      Another hypothesis is that a defect of T helper cell maturation is the pathogenic basis of THI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"       29",
"      </a>",
"      ]. This conclusion was supported by the finding of normal B cell number and function in conjunction with numerical and functional deficiency of CD4-positive T helper cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"       29",
"      </a>",
"      ]. This defect was transient as patients who had recovered from THI normalized CD4-positive T cell number and function. However, this observation has not been observed in many subsequent studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25,26,33,34\">",
"       25,26,33,34",
"      </a>",
"      ]. One possible explanation for this discrepancy is that 3 of the 17 infants in the original study had already recovered from the defect prior to publication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"       29",
"      </a>",
"      ]. It is also conceivable that some of the original patients actually have common variable immunodeficiency (CVID), a disorder known to be associated with a variety of T cell abnormalities.",
"     </li>",
"     <li>",
"      Another possibility, suggested by findings in mice, is that zinc deficiency is causative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/35\">",
"       35",
"      </a>",
"      ]. However, this has not yet been observed in humans.",
"     </li>",
"     <li>",
"      Abnormalities of cytokines may also underlie THI. One study demonstrated an enhanced production of tumor necrosis factor (TNF)-alpha, TNF-beta, and IL-10, while the secretion of other cytokines, such as IL-1, IL-4, and IL-6, was essentially similar in the control and THI patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/34\">",
"       34",
"      </a>",
"      ]. TNF may be involved in the regulation of IgG and IgA production and the balance between TNF production (suppressing IgG synthesis) and IL-10 (inducing IgG switch) may be important for the normal development of IgG-secreting B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/34\">",
"       34",
"      </a>",
"      ]. Further studies are definitely needed to confirm or reject this hypothesis.",
"     </li>",
"     <li>",
"      Finally, if the diagnosis is based on IgG levels of 2 SD (the 95th percentile) below the mean for aged-matched controls, it is possible that patients with THI represent the low extreme variant of the normal age-matched controls, rather than a true abnormality of the immune system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;THI was originally described in two distinct groups of infants. They differ principally by the reason for evaluation of immunodeficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic &mdash; The first group consisted of relatives of patients with known immunodeficiency diseases. They appeared to be in generally good health, and the diagnosis was recognized only because they were screened for serum concentrations of immunoglobulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24,32\">",
"       24,32",
"      </a>",
"      ]. Over time, immunoglobulin levels normalized and the patients remained clinically asymptomatic. The significance of this finding remains unknown.",
"     </li>",
"     <li>",
"      Recurrent or unusual infections &mdash; The second group consisted of infants in whom immunoglobulin measurement was indicated because of recurrent infections starting early in life. The spectrum of severity and type of infections varied from recurrent upper respiratory infections (URIs), otitis media, and bronchitis, to life-threatening infections such as bacteremia and bacterial meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25,27-29,34\">",
"       25,27-29,34",
"      </a>",
"      ]. The initial indication for immunological evaluation was recurrent URIs in one-half of these patients, with or without ear or chest infections. Other indications included recurrent gastroenteritis, severe varicella, prolonged oral thrush, and invasive infection (bacteremia with cellulitis and meningitis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atopic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic diseases are not a prominent clinical characteristic of most patients with THI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. However, one report described four infants with THI who had increased IgE concentrations, and food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/36\">",
"     36",
"    </a>",
"    ]; another study noted that 12 of 15 patients with proven THI had symptoms of either atopic disease or food",
"    <span class=\"nowrap\">",
"     allergy/intolerance",
"    </span>",
"    and the rest had gastrointestinal symptoms without any evidence of atopic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/37\">",
"     37",
"    </a>",
"    ]. Interestingly, none of these patients, who were referred from an allergy unit, presented with infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunoglobulin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above and by definition, patients must have IgG levels that fall",
"    <strong>",
"     at least",
"    </strong>",
"    <strong>",
"     2 SD below",
"    </strong>",
"    the mean for aged-matched controls, with or without diminished values of other Ig isotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematological abnormalities are infrequently described, with transient neutropenia being observed in a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24\">",
"     24",
"    </a>",
"    ]. In our series of 35 patients, we found two patients with transient neutropenia and thrombocytopenia, one with persistent neutropenia (absolute neutrophils &lt;0.5 x",
"    <span class=\"nowrap\">",
"     10(9)/L),",
"    </span>",
"    and one who developed acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies have found that lymphocyte subpopulations and cellular immunity (as measured by proliferation assay in response to mitogens or specific antigens stimulation) are intact, including the level of memory and class-switched B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25,26,33,34,38\">",
"     25,26,33,34,38",
"    </a>",
"    ]. However, one study reported transient numeric and functional abnormalities of CD4 positive T helper cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"     29",
"    </a>",
"    ]. Other investigators have found reduced frequencies of both circulating IgM+ and \"switched\" (IgM-IgD-) memory B cells and an inability to produce IgG in vitro in some children with THI, a phenotype that may identify the subset of patients whose immune defects persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Outcome'",
"    </a>",
"    below.) This reduction in memory B cells has also been identified in children with early-onset CVID and selective IgA deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/41\">",
"     41",
"    </a>",
"    ] and older patients with common variable immunodeficiency (CVID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunization response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with THI usually have normal or near-normal antibody responses to immunization with tetanus and diphtheria toxoids, sometimes well before Ig levels become normal. They also have isohemagglutinin values in the normal range for age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24,33,38\">",
"     24,33,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some children with THI show impaired specific antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated that 11 of 12 THI patients observed before the age of 17 months had made no specific antibodies to a panel of respiratory viruses despite recurrent upper respiratory infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/44\">",
"       44",
"      </a>",
"      ]. Resolution of the THI was marked by the appearance of specific viral antibodies, even before the serum IgG levels returned to normal. Unfortunately, data regarding specific antibodies to immunizations or isohemagglutinins were not reported.",
"     </li>",
"     <li>",
"      A series of 24 children with THI reported that 67 percent of patients had specific titers below the protective level at diagnosis (compared to &gt;85 percent in the general population), despite full primary immunizations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/45\">",
"       45",
"      </a>",
"      ]. Titers to Haemophilus influenzae type b (Hib) were protective in only 17 percent and titers to the serotypes in the conjugate pneumococcal vaccine were protective in 27 to 93 percent. These specific titers improved with reimmunization and resolution of the hypogammaglobulinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other possible associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The series of 24 children with THI, mentioned previously, found varying degrees of developmental delay in 17 percent, and congenital heart disease in 13 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/45\">",
"     45",
"    </a>",
"    ]. This combination of disorders is also seen in children with chromosome 22q11 defects, although the children in this study did not test positively for microdeletions in this chromosome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=see_link\">",
"     \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;THI is a diagnosis of exclusion that should be established in retrospect only after long-term follow-up that includes thorough investigations of serial clinical and laboratory parameters. It is not clear how long of a period patients with THI should be followed, as the process of normalization may require up to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/26\">",
"     26",
"    </a>",
"    ]. In general, patients should experience fewer infections as they grow older, and eventually have normal total serum immunoglobulin levels, IgG subclasses. They are also eventually able to maintain normal specific antibodies for more than a year.",
"   </p>",
"   <p>",
"    One report summarized the experience in patients with suspected THI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25\">",
"     25",
"    </a>",
"    ]: \"According to our own experience, 2 of 10 patients with SCID were initially incorrectly diagnosed as having THI, and both boys died.\"",
"   </p>",
"   <p>",
"    Most patients suspected of having THI present with a history of recurrent respiratory infections, with or without otitis media and pneumonias. Occasionally, some can present with invasive infections such as cellulitis, bacteremia, and even meningitis. Thus, as with other primary immunodeficiency syndromes, a patient who presents with unusual, opportunistic infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent infections requires the appropriate tests to assess the presence or absence of specific defects in the immune system (humoral cellular, phagocytic, or complement). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of patients suspected of having THI consists of an assessment every 6 to 12 months of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall health status. Because the main problem in THI is humoral deficiency, infections are usually caused by pyogenic bacterial organisms such as Streptococcus, Pneumococcus, and Hemophilus.",
"     </li>",
"     <li>",
"      Serum levels of IgG, IgA, and IgM.",
"     </li>",
"     <li>",
"      Serum levels of specific antibodies to previous vaccines. These include polioviruses 1-3 (normal &ge;1:8), tetanus toxoid (normal &ge;0.05",
"      <span class=\"nowrap\">",
"       IU/mL),",
"      </span>",
"      and also the natural occurring isohemagglutinins (normal anti A &gt;1:16, anti B &gt;1:8). Occasionally patients (&gt;two years of age) are immunized with a 23-valent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      , with antibody levels measured 1, 6, and 12 months post-vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphocyte sub-populations and proliferative response to mitogens and specific recall antigens are measured only in cases in which a T cell deficiency is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;THI is, by definition, a self-limited disorder. Thus, this diagnosis cannot be made with confidence until after a full laboratory and clinical recovery. Prior to this point, every effort should therefore be made to differentiate THI from other primary immunodeficiencies that could present similarly, such as autosomal recessive or X-linked agammaglobulinemia (XLA), common variable immune deficiency (CVID), and even a few cases of severe combined immune deficiency (SCID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25\">",
"     25",
"    </a>",
"    ]. Practically, a few patients initially thought to have THI eventually develop symptoms over time and signs more suggestive of another disorder. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Outcome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Agammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;THI is usually easily differentiated from agammaglobulinemia, which is characterized by severe deficiency of all Ig isotypes, inability to produce antibodies, absence of normal peripheral lymphoid tissues, absence or very low number of circulating B lymphocytes, and severe pyogenic infections starting in the first to second year of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21321?source=see_link\">",
"     \"Agammaglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, since the discovery that X-linked agammaglobulinemia (XLA) is associated with mutations in Bruton's tyrosine kinase (BTK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/48\">",
"     48",
"    </a>",
"    ], an increasing number of reports have described a subgroup of patients with atypical clinical and laboratory features, such as low numbers of B cells, low-level antibody production, and less severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These patients, initially thought to have THI, eventually developed more severe disease and laboratory abnormalities more characteristic of XLA later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/49\">",
"     49",
"    </a>",
"    ]. This makes the distinction between THI and XLA sometimes difficult to ascertain at presentation and even over time.",
"   </p>",
"   <p>",
"    Similar ongoing evaluations are performed for patients suspected of having either XLA or THI. The only difference is that a periodic flow cytometer analysis for the presence and number of peripheral B cells is ordered in suspected cases of XLA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVID is one of the most common diagnoses among those with primary immune deficiencies. The age of presentation is usually the second to third decade of life, with Ig levels being low but usually not absent, and most patients suffering from recurrent sinopulmonary infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important factor favoring the diagnosis of CVID rather than THI is the inability of patients with CVID to produce protective levels of specific antibodies, exclusive of IgG. About 60 percent of CVID patients also have variable degrees of impairment in cellular immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. By comparison, patients with THI have intact cellular immune function and normal antibody production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although THI has been recognized for a long time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/1\">",
"     1",
"    </a>",
"    ], few studies have examined long-term outcome. By its definition alone, THI should be transient; spontaneous recovery usually occurs by 9 to 15 months of age, with levels of IgG becoming normal by two to four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/7,51,52\">",
"     7,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, however, abnormal IgG levels may not be limited to the period of infancy. One study, for example, noted that a few patients did not recover completely until five years of age and two patients had persistent selective IgA deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar findings have been reported in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24,52,53\">",
"     24,52,53",
"    </a>",
"    ]. The significance of a possible correlation with selective IgA deficiency is unclear. Selective IgA deficiency is the most common immune abnormality, occurring at a frequency of up to 1:300 among some populations. Most patients are essentially asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study of 35 patients, we followed the evolution of hypogammaglobulinemia, specific antibody titers, and clinical manifestations for a period of ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/26\">",
"     26",
"    </a>",
"    ]. In all patients, the indication for immune evaluation was recurrent infections. Three different patterns of disease course were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first and most common pattern included patients who experienced fewer infections as they grew older, and eventually, had normal total serum IgG levels, IgG subclass distribution, and specific antibody production. Some presented with non-protective levels of a specific antibody, but responded normally to reimmunization and were able to sustain these values. This process may span a decade and may include a transient phase whereby IgG subclasses may become unbalanced. Only then can these patients be identified as having THI (group I, n = 29) (",
"      <a class=\"graphic graphic_figure graphicRef69448 \" href=\"mobipreview.htm?29/26/30127\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The second group consisted of patients who continued to suffer repeated infections and to have low IgG levels and poor antibody titers despite reimmunization. These patients subsequently required permanent intravenous immunoglobulin (IVIG) replacement therapy. This group can therefore be reclassified as having CVID despite the unusual presentation early in infancy (group II, n = 3) (",
"      <a class=\"graphic graphic_figure graphicRef69445 \" href=\"mobipreview.htm?10/52/11087\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The third pattern includes patients whose serum IgG levels become normal but continued to experience significant infections. Upon reimmunization, they had a satisfactory response, but demonstrated a gradual decline to non-protective levels within one year and subsequently required IVIG, despite having \"normal\" IgG levels. This group can therefore be classified as having dysgammaglobulinemia (group III, n = 3) (",
"      <a class=\"graphic graphic_figure graphicRef69445 \" href=\"mobipreview.htm?10/52/11087\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In conclusion, although it is impossible to predict patient outcome early at presentation, the presence of invasive infections and low antibody levels at presentation significantly predict the development of permanent antibody deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis should be considered mainly for patients with recurrent respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ear infections. The preferred option is a single daily dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/8/5255?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component), or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice per day).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunoglobulin replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin replacement therapy remains a controversial modality in the treatment of these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link&amp;anchor=H41#H41\">",
"     \"Approach to the child with recurrent infections\", section on 'Management of the child with recurrent infection'",
"    </a>",
"    .) There are several points to be considered before any decision can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoglobulin replacement is an expensive modality of treatment.",
"     </li>",
"     <li>",
"      The potential for transferring hazardous infective agents is still an unresolved problem, despite significant improvement having been achieved in screening and purification methods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse reactions, including sometimes life-threatening events, are not uncommon in patients receiving immune globulin preparations. It should be noted that IgA deficient patients may suffer anaphylactic reactions when an IgA-containing product is administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=see_link\">",
"       \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The passively administered Ig could further delay the onset of synthesis of the patient's own Igs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most THI patients suffer only mild recurrent infections, mainly of the respiratory system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All these considerations support the concept that low IgG alone is an insufficient indication for immunoglobulin replacement therapy. The decision to initiate this therapy should be based principally upon clinical grounds and reserved for patients with recurrent severe infections who did not respond to antibiotic prophylaxis. Dosing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the time of treatment, there is no need to vaccinate these patients as they are protected by the passive transfer of pooled immunoglobulin. In addition, patients should not be vaccinated for three months after Ig replacement is stopped, to avoid interference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reported cases were treated with immunoglobulin for short periods of time, ranging from a single injection to up to 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25,44\">",
"     25,44",
"    </a>",
"    ]. The decision as to when to stop replacement therapy should not be based only upon a significant decrease in the number and severity of infections. Nevertheless, other factors, such as spontaneous increase in IgA and IgM concentrations and increases in isohemagglutinin titers (IgM isotype antibodies), are important. After discontinuation of therapy, patients should be followed periodically until a complete clinical and laboratory is accomplished and sustained for a substantial period of time before a declaration of full recovery can be made. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following defining criteria have been suggested for transient hypogammaglobulinemia of infancy: the presence of IgG levels at least 2 SD below the mean for aged-matched controls as an invariant criteria, with or without diminished values of other Ig isotypes, that persists beyond six months of age and occurs in the absence of other immunodeficiency conditions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause(s) of transient hypogammaglobulinemia of infancy remains unknown. It is possible that patients with transient hypogammaglobulinemia of infancy represent the low extreme variant of normal, rather than a true abnormality of the immune system. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with recurrent or unusual infections early in life or with a family history of immunodeficiency. They usually have normal or near-normal antibody responses to immunization with tetanus and diphtheria toxoids, sometimes well before immunoglobulin levels become normal. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical and laboratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient hypogammaglobulinemia of infancy is a diagnosis of exclusion that should be established in retrospect only after long-term follow-up that includes thorough investigations of serial clinical and laboratory parameters. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every effort should be made to differentiate transient hypogammaglobulinemia of infancy from other primary immunodeficiencies that could present similarly, such as autosomal recessive or X-linked agammaglobulinemia (XLA), common variable immune deficiency (CVID), and even a few cases of severe combined immune deficiency (SCID). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spontaneous recovery usually occurs by 9 to 15 months of age, with levels of IgG becoming normal by two to four years of age. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antibiotic prophylaxis for patients with transient hypogammaglobulinemia who have recurrent sinopulmonary infections. The preferred option is a single daily dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/8/5255?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component), or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice per day). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that immune globulin replacement therapy be reserved for patients with transient hypogammaglobulinemia who have recurrent severe infections and do not respond to antibiotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/1\">",
"      Gitlin D, Janeway CA. Agammaglobulinemia, congenital, acquired and transient forms. Prog Hematol 1956; 1:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/2\">",
"      Kohler PF, Farr RS. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature 1966; 210:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/3\">",
"      Hobbs JR, Davis JA. Serum gamma-G-globulin levels and gestational age in premature babies. Lancet 1967; 1:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/4\">",
"      Shapiro R, Beatty DW, Woods DL, Malan AF. Serum complement and immunoglobulin values in small-for-gestational-age infants. J Pediatr 1981; 99:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/5\">",
"      Einhorn MS, Granoff DM, Nahm MH, et al. Concentrations of antibodies in paired maternal and infant sera: relationship to IgG subclass. J Pediatr 1987; 111:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/6\">",
"      Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986; 20:899.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Immunologic disorders in infants and children, Stiehm ER (Ed), WB Saunders, Philadelphia 1996. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/8\">",
"      Natvig JB, Kunkel HG. Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes. Adv Immunol 1973; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/9\">",
"      Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/10\">",
"      Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 1990; 9:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/11\">",
"      Insel RA, Anderson PW. IgG subclass distribution of antibody induced by immunization with the isolated and protein-conjugated polysaccharide of H. influenzae b and G2m(n) distribution of serum IgG2 in man. Monogr Allergy 1988; 23:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/12\">",
"      Mellbye OJ, Natvig JB. Presence and origin of human IgG subclass proteins in newborns. Vox Sang 1973; 24:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/13\">",
"      Schur PH, Rosen F, Norman ME. Immunoglobulin subclasses in normal children. Pediatr Res 1979; 13:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/14\">",
"      French M. Serum IgG subclasses in normal adults. Monogr Allergy 1986; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/15\">",
"      Morell A, Skvaril F, Hitzig WH, Barandun S. IgG subclasses: development of the serum concentrations in \"normal\" infants and children. J Pediatr 1972; 80:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/16\">",
"      Shackelford PG, Granoff DM, Madassery JV, et al. Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2. Pediatr Res 1990; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/17\">",
"      Ambrosino DM, Siber GR, Chilmonczyk BA, et al. An immunodeficiency characterized by impaired antibody responses to polysaccharides. N Engl J Med 1987; 316:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/18\">",
"      Ambrosino DM, Umetsu DT, Siber GR, et al. Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. J Allergy Clin Immunol 1988; 81:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/19\">",
"      Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002; 2:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/20\">",
"      Atkinson AR, Roifman CM. Low serum immunoglobulin G2 levels in infancy can be transient. Pediatrics 2007; 120:e543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/21\">",
"      Alford CA Jr, Stagno S, Reynolds DW. Diagnosis of chronic perinatal infections. Am J Dis Child 1975; 129:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/22\">",
"      Primary immunodeficiency diseases. Report of a WHO scientific group. Immunodefic Rev 1992; 3:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/23\">",
"      Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol 1999; 118 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/24\">",
"      Tiller TL Jr, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr 1978; 92:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/25\">",
"      Dressler F, Peter HH, M&uuml;ller W, Rieger CH. Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand 1989; 78:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/26\">",
"      Dalal I, Reid B, Nisbet-Brown E, Roifman CM. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998; 133:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/27\">",
"      McGeady SJ. Transient hypogammaglobulinemia of infancy: need to reconsider name and definition. J Pediatr 1987; 110:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/28\">",
"      Qian JH, Zhu JX, Zhu XD, Chen TX. Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infancy. Chin Med J (Engl) 2009; 122:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/29\">",
"      Siegel RL, Issekutz T, Schwaber J, et al. Deficiency of T helper cells in transient hypogammaglobulinemia of infancy. N Engl J Med 1981; 305:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/30\">",
"      Fudenberg HH. Antibody to hereditary human gamma-globulin (GM) factor resulting from maternal-fetal incompatibility. Science 1964; 145:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/31\">",
"      Nathenson G, Schorr JB, Litwin SD. Gm factor fetomaternal gamma globulin incompatibility. Pediatr Res 1971; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/32\">",
"      Soothill JF. Immunoglobulins in first-degree relatives of patients with hypogammaglobulinaemia. Transient hypogammaglobulinaemia: a possible manifestation of heterozygocity. Lancet 1968; 1:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/33\">",
"      Rieger CH, Nelson LA, Peri BA, et al. Transient hypogammaglobulinemia of infancy. J Pediatr 1977; 91:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/34\">",
"      Kowalczyk D, Mytar B, Zembala M. Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency. J Allergy Clin Immunol 1997; 100:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/35\">",
"      Lentz D, Gershwin ME. Is transient hypogammaglobulinemia of infancy a manifestation of zinc deficiency? Dev Comp Immunol 1984; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/36\">",
"      Fineman SM, Rosen FS, Geha RS. Transient hypogammaglobulinemia, elevated immunoglobulin E levels, and food allergy. J Allergy Clin Immunol 1979; 64:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/37\">",
"      Walker AM, Kemp AS, Hill DJ, Shelton MJ. Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities. Arch Dis Child 1994; 70:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/38\">",
"      Kili&ccedil; SS, Tezcan I, Sanal O, et al. Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases. Pediatr Int 2000; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/39\">",
"      Moschese V, Carsetti R, Graziani S, et al. Memory B-cell subsets as a predictive marker of outcome in hypogammaglobulinemia during infancy. J Allergy Clin Immunol 2007; 120:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/40\">",
"      Moschese V, Graziani S, Avanzini MA, et al. A prospective study on children with initial diagnosis of transient hypogammaglobulinemia of infancy: results from the Italian Primary Immunodeficiency Network. Int J Immunopathol Pharmacol 2008; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/41\">",
"      Bukowska-Strakov&aacute; K, Kowalczyk D, Baran J, et al. The B-cell compartment in the peripheral blood of children with different types of primary humoral immunodeficiency. Pediatr Res 2009; 66:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/42\">",
"      Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/43\">",
"      Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/44\">",
"      Cano F, Mayo DR, Ballow M. Absent specific viral antibodies in patients with transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1990; 85:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/45\">",
"      Dorsey MJ, Orange JS. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 2006; 97:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/46\">",
"      Buckley RH. Immunodeficiency diseases. JAMA 1992; 268:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/47\">",
"      Iseki M, Heiner DC. Immunodeficiency disorders. Pediatr Rev 1993; 14:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/48\">",
"      Vetrie D, Vorechovsk&yacute; I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/49\">",
"      Kornfeld SJ, Kratz J, Haire RN, et al. X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1995; 95:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/50\">",
"      Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 1994; 330:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/51\">",
"      Rosen FS, Janeway CA. The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med 1966; 275:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/52\">",
"      Dou F, Ikincioullari A, Babacan E. Transient hypogammaglobulinemia of infancy and early childhood: outcome of 30 cases. Turk J Pediatr 2004; 46:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/53\">",
"      Benderly A, Pollack S, Etzioni A. Transient hypogammaglobulinemia of infancy with severe bacterial infections and persistent IgA deficiency. Isr J Med Sci 1986; 22:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/55\">",
"      Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41544/abstract/56\">",
"      Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. (2). N Engl J Med 1984; 311:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5951 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41544=[""].join("\n");
var outline_f40_36_41544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOGLOBULIN LEVELS IN INFANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunoglobulin G",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IgG subclasses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other Ig isotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommended diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atopic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunoglobulin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunization response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other possible associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunoglobulin replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5951|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/25/32157\" title=\"figure 1\">",
"      Serum IgG levels less than 5 y",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/26/30127\" title=\"figure 2\">",
"      Normal Ab IgG Patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/52/11087\" title=\"figure 3\">",
"      Abnormal Ab IgG Patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/48/6925\" title=\"table 1\">",
"      Levels of IgG subclasses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41545="Atypical (dysplastic) nevi";
var content_f40_36_41545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atypical (dysplastic) nevi",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Allan Halpern, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Elizabeth Quigley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/36/41545/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/36/41545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14454900\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi, also known as dysplastic nevi, are benign acquired melanocytic neoplasms. Atypical nevi share some of the clinical features of melanoma, such as asymmetry, irregular borders, multiple colors, and diameter &gt;5 mm (",
"    <a class=\"graphic graphic_picture graphicRef83351 \" href=\"mobipreview.htm?7/50/7972\">",
"     picture 1A",
"    </a>",
"    ). They occur sporadically or in a familial setting. Histologically, they may demonstrate architectural disorder, cytologic atypia, and a variable amount of inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms &ldquo;atypical nevi&rdquo; and &ldquo;dysplastic nevi&rdquo; are clinically used interchangeably, although in theory a dysplastic nevus refers to a histologic diagnosis.",
"   </p>",
"   <p>",
"    Although atypical nevi are benign lesions, they are strong phenotypic markers of an increased risk of melanoma, especially in individuals with numerous nevi",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a family history of melanoma. Infrequently, atypical nevi may develop into melanoma.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features, diagnosis, and management of atypical nevi. Congenital nevi and common acquired melanocytic nevi are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=see_link\">",
"     \"Congenital melanocytic nevi and speckled lentiginous nevi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link\">",
"     \"Acquired melanocytic nevi (moles)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1007470\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND HISTORICAL BACKGROUND",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The terms &ldquo;B-K mole&rdquo;, &ldquo;B-K mole syndrome&rdquo;, and &ldquo;familial atypical multiple mole and melanoma syndrome&rdquo; (FAMMM) were first used in 1978 to describe a cutaneous phenotype characterized by multiple large atypical moles associated with a family history of melanoma in two or more first-degree relatives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. The terms &ldquo;B-K mole&rdquo; and &ldquo;B-K mole syndrome&rdquo; are no longer in common use.",
"     </li>",
"     <li>",
"      The term &rdquo;dysplastic nevus syndrome&rdquo; was introduced at the same time to describe individuals with sporadic (nonfamilial) melanoma who had any number of large clinically and histologically atypical nevi [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The term &ldquo;atypical mole syndrome&rdquo; was subsequently applied to patients with many nevi (&gt;100) including some larger than 8 mm and with atypical features (",
"      <a class=\"graphic graphic_table graphicRef86179 \" href=\"mobipreview.htm?19/39/20092\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In 1992, the National Institutes of Health in the United States issued a Consensus Statement recommending the term \"dysplastic nevus\" be replaced with \"atypical nevus\" and that, histologically, lesions be diagnosed as \"nevi with architectural disorder with a statement as to the presence and degree of melanocytic atypia&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, the panel recommended the syndrome for melanoma-prone families be referred to as familial atypical mole and melanoma (FAMM) syndrome. However, the terms dysplastic nevus and FAMMM remain in common use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454921\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of any atypical nevi in white-skinned populations ranges from 2 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Some of the prevalence variation is explained by differences in the diagnostic criteria used. In patients with a personal history of melanoma, the estimated prevalence is 30 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The prevalence of the FAMMM syndrome in the general population is unknown. In a study of 385 families with three or more patients with melanoma from the Melanoma Genetics Consortium, 39 percent of families had CDKN2A mutations, ranging from 20 percent (32 of 162) in Australia to 45 percent (29 of 65) in North America, and 57 percent (89 of 157) in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H237810\">",
"     'FAMMM syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H416834\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of atypical nevi lies in their association with an increased risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/10,15-20\">",
"     10,15-20",
"    </a>",
"    ]. Individuals with atypical nevi have a 3- to 20-fold higher risk of developing a melanoma than individuals without atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/17,21-23\">",
"     17,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of melanoma increases in a dose-response fashion with the number of clinically atypical nevi and is greatest in individuals with atypical nevi and personal or family history of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/17,21,24\">",
"     17,21,24",
"    </a>",
"    ]. In a meta-analysis of observational studies, the relative risk of melanoma associated with atypical nevi was 1.5 (95% CI 1.3-1.6) for the presence of a single atypical nevus and 6.36 (95% CI 3.80&ndash;10.33) for five atypical nevi versus none [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454935\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and density of nevi appear to be predominantly under genetic control, with ultraviolet light exposure playing an important modifying role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Small studies have demonstrated activating mutations of the oncogene",
"    <em>",
"     BRAF",
"    </em>",
"    and allelic deletions of",
"    <em>",
"     p16",
"    </em>",
"    and",
"    <em>",
"     p53",
"    </em>",
"    in nevus cells of common and atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. However, a specific pattern of somatic mutations has not been identified. Germline mutations of the melanoma susceptibility genes (",
"    <em>",
"     CDKN2A, ARF, CDK4, PTEN, BRAF",
"    </em>",
"    ) have not been found in individuals with sporadic atypical mole syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237810\">",
"    <span class=\"h2\">",
"     FAMMM syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The familial atypical multiple mole and melanoma (FAMMM) syndrome is an autosomal dominant condition characterized by a high number of common and atypical nevi (&gt;50) and history of melanoma in one or more first- or second-degree relative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/34\">",
"     34",
"    </a>",
"    ]. This syndrome is associated with mutations in the",
"    <em>",
"     CDKN2A",
"    </em>",
"    gene with reduced penetrance and variable expressivity.",
"   </p>",
"   <p>",
"    The",
"    <em>",
"     CDKN2A",
"    </em>",
"    gene is located on chromosome 9p21.3 and encodes the proteins p14ARF, p16(INK4), p15(INK4b), p18(INK4), and p19ARF, which are involved in the regulation of critical cell cycle pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients harboring the specific",
"    <em>",
"     CDKN2A",
"    </em>",
"    mutation have an increased risk of early or multiple melanomas and other primary cancers, in particular pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454942\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi usually first appear during puberty and may develop throughout life. In contrast, acquired common nevi appear after the age of six months, reach a peak count in the third decade, and then slowly regress with age. Atypical nevi arising on the scalp, breasts, or buttocks during childhood may be an early sign of high total-body nevus count in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atypical nevi are dynamic in their clinical appearance. In a prospective study of 593 atypical nevi in 153 patients, 50 percent of nevi changed over an average of 89 months of follow-up, with 15 percent showing more atypical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of atypical nevi as precursors of melanoma is controversial. Although the presence of atypical nevi is a strong risk factor for melanoma, approximately half of melanomas arising in patients with atypical nevi develop de novo, and do not evolve from a precursor atypical nevus. This is also true in patients with multiple atypical nevi. However, although the risk of an individual atypical nevus progressing to melanoma is very small, it does occur, and has been documented through sequential photographs and histologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1008077\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi are most often seen on the trunk and extremities, although they can develop anywhere on the body, including the scalp, breasts, buttocks, and genitalia (",
"    <a class=\"graphic graphic_picture graphicRef78891 graphicRef53622 \" href=\"mobipreview.htm?34/29/35289\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/44\">",
"     44",
"    </a>",
"    ]. They rarely develop on the chronically sun-exposed skin of the face or hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features that characterize a nevus as atypical include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter in one dimension &gt;5 mm (",
"      <a class=\"graphic graphic_picture graphicRef80725 \" href=\"mobipreview.htm?7/52/8006\">",
"       picture 1B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prominent macular component, sometimes with a papular center (&ldquo;fried egg&rdquo; or &ldquo;target&rdquo; appearance) (",
"      <a class=\"graphic graphic_picture graphicRef83466 \" href=\"mobipreview.htm?20/35/21042\">",
"       picture 3",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Mammillated (cobblestone) topography (",
"      <a class=\"graphic graphic_picture graphicRef80725 \" href=\"mobipreview.htm?7/52/8006\">",
"       picture 1B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Asymmetry (one half of the lesion does not match the other in terms of shape or color)",
"     </li>",
"     <li>",
"      Notched, irregular, or ill-defined borders fading into surrounding skin (",
"      <a class=\"graphic graphic_picture graphicRef70320 \" href=\"mobipreview.htm?13/49/14099\">",
"       picture 1C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Variegated color, with areas of pink, tan, brown, or dark brown (",
"      <a class=\"graphic graphic_picture graphicRef83351 \" href=\"mobipreview.htm?7/50/7972\">",
"       picture 1A",
"      </a>",
"      ). Other colors (eg, blue, red, or white) are not usually seen in atypical nevi and their presence increases the probability that the lesion is a melanoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although atypical nevi share some of the clinical characteristics of melanoma, they are generally stable and most of them will never develop a melanoma. Progression to melanoma most often manifests as a new focal area of deep pigmentation or firm elevation (",
"    <a class=\"graphic graphic_picture graphicRef83545 graphicRef83546 \" href=\"mobipreview.htm?43/38/44648\">",
"     picture 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960751\">",
"    <span class=\"h2\">",
"     The \"signature nevus\" and \"ugly duckling\" sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with multiple nevi, the predominant group of nevi that share similar clinical and dermoscopic features defines the &ldquo;signature nevus&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The identification of nevi that appear different from the signature nevi, called &ldquo;ugly ducklings&rdquo; or &ldquo;outliers,&rdquo; has been suggested as a screening method for the detection of melanoma in patients with many nevi, including those with many atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37327243\">",
"    <span class=\"h1\">",
"     DERMOSCOPIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;On dermoscopic examination, many atypical nevi fall into one of ten benign dermoscopic patterns (",
"    <a class=\"graphic graphic_figure graphicRef61160 \" href=\"mobipreview.htm?40/30/41449\">",
"     figure 1",
"    </a>",
"    ). These patterns, identified by examining large series of histologically confirmed atypical nevi, are based upon structural features and pigment distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link&amp;anchor=H2297773#H2297773\">",
"     \"Dermoscopic evaluation of skin lesions\", section on 'Benign nevi: global and local features'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reticular diffuse (",
"      <a class=\"graphic graphic_picture graphicRef54776 \" href=\"mobipreview.htm?25/34/26144\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reticular patchy (",
"      <a class=\"graphic graphic_picture graphicRef62442 \" href=\"mobipreview.htm?15/1/15377\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reticular with central hypopigmentation (",
"      <a class=\"graphic graphic_picture graphicRef78278 \" href=\"mobipreview.htm?30/1/30737\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reticular with central hyperpigmentation (",
"      <a class=\"graphic graphic_picture graphicRef57412 \" href=\"mobipreview.htm?15/22/15714\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Homogeneous (",
"      <a class=\"graphic graphic_picture graphicRef69190 \" href=\"mobipreview.htm?20/30/20962\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral reticular with central globules (",
"      <a class=\"graphic graphic_picture graphicRef80161 \" href=\"mobipreview.htm?8/27/8626\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral globular (",
"      <a class=\"graphic graphic_picture graphicRef55874 \" href=\"mobipreview.htm?41/28/42434\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Globular (",
"      <a class=\"graphic graphic_picture graphicRef67691 \" href=\"mobipreview.htm?15/45/16080\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Two-component pattern (",
"      <a class=\"graphic graphic_picture graphicRef78854 \" href=\"mobipreview.htm?29/58/30639\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multicomponent pattern (",
"      <a class=\"graphic graphic_picture graphicRef58486 \" href=\"mobipreview.htm?11/52/12096\">",
"       picture 14",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Atypical nevi that have eccentric peripheral hyperpigmentation or a multicomponent pattern are simulators of melanoma. For this type of lesion, short term digital dermoscopic monitoring or biopsy and histologic examination are necessary to exclude melanoma. (See",
"    <a class=\"local\" href=\"#H14455005\">",
"     'Short-term monitoring'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H647927\">",
"     'Biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454956\">",
"    <span class=\"h1\">",
"     HISTOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most, but not all, clinically atypical nevi manifest histologic dysplasia, which includes architectural disorder, cytologic atypia, and host response features (eg, lymphocytic dermal infiltration, concentric eosinophilic fibrosis, lamellar fibroplasia, and neovascularization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/9,53\">",
"     9,53",
"    </a>",
"    ]. It should be noted that there is a continuum in the features that distinguish an atypical nevus from an in situ melanoma, and the line of demarcation between these diagnoses can be uncertain.",
"   </p>",
"   <p>",
"    Architectural disorder is defined by the combination of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lentiginous melanocytic hyperplasia, with elongation of rete ridges, and proliferation of single or nested melanocytes in the basal layer.",
"     </li>",
"     <li>",
"      Peripheral extension of the junctional component beyond the dermal component (shoulder phenomenon).",
"     </li>",
"     <li>",
"      Nests of melanocytes distributed at the sides of rete or at the suprapapillary dermoepidermal junction.",
"     </li>",
"     <li>",
"      Bridging or fusion of intraepidermal melanocytic nests across adjacent retia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytological atypia is defined as the presence of a variable proportion of atypical melanocytes and is graded as mild, moderate, or severe. Atypical melanocytes are larger than normal, have large hyperchromatic nuclei, irregular nuclear shape and nuclear polymorphism, abnormal chromatin pattern, and prominent nucleoli.",
"   </p>",
"   <p>",
"    There are no universally accepted criteria for the diagnosis or grading of cytologic atypia. Several interobserver agreement studies found a good level of agreement between pathologists on the diagnosis of atypical nevi versus melanoma or benign melanocytic nevi, but only a fair agreement in grading cytologic atypia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the atypia grade in the assessment of melanoma risk for individual patients is uncertain. An observational study found a higher risk of melanoma in patients who had nevi with high grade histologic atypia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237624\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of atypical nevus is usually clinical, based upon the finding of a predominantly macular pigmented lesion that is larger than common melanocytic nevi (&gt;5 mm), with irregular shape, ill-defined borders, and variable color (",
"    <a class=\"graphic graphic_picture graphicRef83351 graphicRef80725 graphicRef70320 \" href=\"mobipreview.htm?29/5/29786\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dermoscopy is not necessary to establish the diagnosis of an atypical nevus when the clinical characteristics are well-defined, but for many lesions, dermoscopy can be helpful to clarify the benign nature of the lesion and distinguish it from a melanoma. (See",
"    <a class=\"local\" href=\"#H1008077\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H37327243\">",
"     'Dermoscopic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biopsy is not indicated to confirm the diagnosis of an atypical nevus. Excisional biopsy and histologic confirmation are required only for lesions that are clinically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermoscopically suspicious for melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55979238\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical nevi should be differentiated from benign and malignant melanocytic or keratinocytic lesions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Melanoma",
"      </strong>",
"      &minus; Distinguishing atypical nevi from superficial spreading melanoma (",
"      <a class=\"graphic graphic_picture graphicRef71893 graphicRef82173 graphicRef61158 graphicRef74278 \" href=\"mobipreview.htm?38/10/39082\">",
"       picture 15A-D",
"      </a>",
"      ) is clearly a major difficulty in examining a patient with multiple atypical nevi (",
"      <a class=\"graphic graphic_table graphicRef83534 \" href=\"mobipreview.htm?41/26/42411\">",
"       table 2",
"      </a>",
"      ). Since the clinical features of atypical nevi are in continuum with those of in situ melanoma, the clinician must have a sufficiently low threshold for excision to avoid missing a melanoma. Clinical findings that raise the suspicion of melanoma include (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H47495879#H47495879\">",
"       \"Skin examination and clinical features of melanoma\", section on 'Clinical diagnosis'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Shades of blue-gray, red, or white color, which are unusual in atypical nevi.",
"     </li>",
"     <li>",
"      A lesion that is clinically or dermoscopically different from the predominant nevus pattern in an individual patient (the &ldquo;ugly duckling&rdquo; sign).",
"     </li>",
"     <li>",
"      A history of rapid change (in size, color, or shape) in a preexisting nevus over months.",
"     </li>",
"     <li>",
"      A newly developed pigmented lesion in an individual older than 40 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On dermoscopy, melanoma usually deviates from the benign nevus patterns and manifests specific melanoma features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link&amp;anchor=H2297820#H2297820\">",
"     \"Dermoscopic evaluation of skin lesions\", section on 'Melanoma: global and local features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any lesions with clinical or dermoscopic features that are suspicious of melanoma should be excised and sent for histologic examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Common acquired nevi",
"      </strong>",
"      &minus; Common nevi tend to be &le;5 mm in diameter and symmetric, with a homogeneous surface, even pigmentation, round or oval shape, and well-demarcated border (",
"      <a class=\"graphic graphic_table graphicRef83534 \" href=\"mobipreview.htm?41/26/42411\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81931 graphicRef57022 \" href=\"mobipreview.htm?0/32/519\">",
"       picture 16A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link&amp;anchor=H7#H7\">",
"       \"Acquired melanocytic nevi (moles)\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Small congenital nev",
"      </strong>",
"      i &minus; Small (&lt;1.5 cm) congenital nevi (",
"      <a class=\"graphic graphic_picture graphicRef83920 graphicRef74734 \" href=\"mobipreview.htm?3/4/3143\">",
"       picture 17A-B",
"      </a>",
"      ) are present since birth or the first few months of life. They typically have a regular sharply demarcated border, tan to black color, and a smooth, pebbly, or verrucous surface (",
"      <a class=\"graphic graphic_table graphicRef83534 \" href=\"mobipreview.htm?41/26/42411\">",
"       table 2",
"      </a>",
"      ). However, some congenital nevi may have irregular and poorly demarcated borders and very dark or discontinuous pigmentation. These atypical lesions require biopsy and histologic evaluation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=see_link&amp;anchor=H4#H4\">",
"       \"Congenital melanocytic nevi and speckled lentiginous nevi\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pigmented basal cell carcinoma",
"      </strong>",
"      &minus; Pigmented basal cell carcinomas may clinically mimic an atypical melanocytic lesion (",
"      <a class=\"graphic graphic_picture graphicRef83549 \" href=\"mobipreview.htm?31/58/32676\">",
"       picture 18",
"      </a>",
"      ). They are more often nodular and may have irregular pigmentation ranging from dark brown to black. Although dermoscopy may be helpful in differentiating pigmented basal cell carcinomas from atypical nevi or melanoma, biopsy and histologic examination are necessary for definitive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H21#H21\">",
"       \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link&amp;anchor=H610193#H610193\">",
"       \"Dermoscopic evaluation of skin lesions\", section on 'Criteria for basal cell carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Seborrheic keratosis",
"      </strong>",
"      &minus; Seborrheic keratoses typically have uniform color ranging from pink to dark brown or black, well-circumscribed borders, a dull surface, and a &ldquo;stuck on&rdquo; appearance (",
"      <a class=\"graphic graphic_picture graphicRef83550 graphicRef58923 graphicRef64738 \" href=\"mobipreview.htm?30/54/31594\">",
"       picture 19A-C",
"      </a>",
"      ). Dermoscopic examination is useful in differentiating seborrheic keratoses from atypical nevi. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link&amp;anchor=H610256#H610256\">",
"       \"Dermoscopic evaluation of skin lesions\", section on 'Criteria for seborrheic keratoses'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454977\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atypical nevi are at increased risk of developing melanoma. Risk assessment, prevention, and early detection of melanoma are key aspects of management in these patients, which may involve: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessing the patient&rsquo;s personal and family history of melanoma &nbsp;",
"     </li>",
"     <li>",
"      Total body skin examination",
"     </li>",
"     <li>",
"      Use of diagnostic aids such as dermoscopy and total body photography",
"     </li>",
"     <li>",
"      Excision and histologic examination of suspicious lesions",
"     </li>",
"     <li>",
"      Education on skin self-examination and sun protection",
"     </li>",
"     <li>",
"      Screening of family members",
"     </li>",
"     <li>",
"      Genetic counseling if appropriate",
"     </li>",
"     <li>",
"      Routine ophthalmologic examination",
"     </li>",
"     <li>",
"      Lifelong follow-up",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962027\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atypical nevi should be questioned about:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of atypical nevi",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      melanoma",
"     </li>",
"     <li>",
"      Personal history of melanoma",
"     </li>",
"     <li>",
"      Changes or symptoms related to their nevi",
"     </li>",
"     <li>",
"      Sun exposure habits",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454984\">",
"    <span class=\"h2\">",
"     Skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with atypical nevi, regular skin examination beginning around puberty provides an opportunity for education regarding sun avoidance, the importance of self skin examinations, and education in the early warning signs of melanoma.",
"   </p>",
"   <p>",
"    Skin examination of patients with atypical nevi should include the scalp, buttocks, groin, palms, and soles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/58\">",
"     58",
"    </a>",
"    ]. Skin examination requires a source of bright light and, ideally, a magnifying lens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H43034853#H43034853\">",
"     \"Skin examination and clinical features of melanoma\", section on 'Total body skin examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total number of nevi should be approximated. Nevi should be examined for the ABCDE features of melanoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H47495344#H47495344\">",
"     \"Skin examination and clinical features of melanoma\", section on 'ABCDE rule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any nevus that is remarkably different from the predominant nevus pattern (\"ugly duckling&rdquo; nevus) should undergo a closer examination. Any lesions for which malignancy cannot be reliably excluded should be biopsied and sent for histologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454991\">",
"    <span class=\"h2\">",
"     Total body photography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical identification of new or changed lesions in patients with numerous nevi can be challenging (",
"    <a class=\"graphic graphic_picture graphicRef83737 \" href=\"mobipreview.htm?39/1/39954\">",
"     picture 20",
"    </a>",
"    ). Use of baseline total body photography for comparison on each follow-up examination may facilitate the detection of new lesions or changes in preexisting nevi.",
"   </p>",
"   <p>",
"    The impact of total body photography on early diagnosis of melanoma and survival in high-risk patients has not been evaluated in randomized trials or large observational studies. However, several retrospective studies provide evidence that this surveillance technique may be helpful in detecting early melanoma in patients with multiple atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/16,17,59-62\">",
"     16,17,59-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14454998\">",
"    <span class=\"h2\">",
"     Dermoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoscopy has been shown to improve the sensitivity and specificity of melanoma diagnosis for clinicians with adequate training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Several studies support its usefulness, in conjunction with total body photography and clinical examination, in the early diagnosis of melanoma in patients with atypical nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/61,65-67\">",
"     61,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions are evaluated by using one of the several algorithms designed to differentiate benign from suspicious or malignant lesions, including Menzies method, the ABCD rule of dermoscopy, the seven-point checklist, or pattern analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link&amp;anchor=H18480302#H18480302\">",
"     \"Dermoscopic evaluation of skin lesions\", section on 'Second step: benign nevus versus suspicious lesion or melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atypical nevi with dermoscopic features that deviate from the benign nevus patterns and are suspicious of melanoma should be biopsied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37327243\">",
"     'Dermoscopic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14455005\">",
"    <span class=\"h3\">",
"     Short-term monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term monitoring of suspicious lesions by sequential digital dermoscopy may be useful in identifying early melanomas, especially featureless melanomas, on the basis of changes detected in sequential images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. A reasonable interval for short-term mole monitoring is three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/68\">",
"     68",
"    </a>",
"    ]. Approximately 10 to 20 percent of changing lesions on short-term monitoring have been shown to be melanoma on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/68,70\">",
"     68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647927\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic excision of atypical nevi is not recommended, because the risk of melanoma developing in an individual atypical nevus is extremely low and the majority of melanomas arises de novo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/43\">",
"     43",
"    </a>",
"    ]. However, new, changing, or symptomatic lesions that are suspicious of melanoma on clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermoscopic examination should be excised and sent for histologic examination. For clinicians who are proficient in the use of dermoscopy, dermoscopic examination may be helpful in deciding whether an atypical nevus should be biopsied or monitored. (See",
"    <a class=\"local\" href=\"#H37327243\">",
"     'Dermoscopic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless of the surgical technique employed (eg, scalpel excision, punch biopsy, or",
"    <span class=\"nowrap\">",
"     shave/saucerization),",
"    </span>",
"    the lesion should be removed entirely with a 2 to 3 mm margin of normal skin beyond the area of pigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/44,45,71\">",
"     44,45,71",
"    </a>",
"    ]. Partial or superficial biopsies are discouraged to avoid sampling error and reduce the risk of nevus recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/72\">",
"     72",
"    </a>",
"    ]. Persistent or recurrent pigmentation at the biopsy site can be difficult to differentiate from melanoma clinically and histologically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647934\">",
"    <span class=\"h3\">",
"     Reexcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reexcision of atypical nevi with positive margins on histologic examination is a common practice among dermatologists, although there are no universally accepted guidelines. In a survey of fellows of the American Academy of Dermatology, 67 percent of respondents reported that they would reexcise atypical nevi with positive margins (the grade of atypia was not specified) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/75\">",
"     75",
"    </a>",
"    ]. Another survey found that either the grade of atypia or margin involvement were important in determining the surgical decision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/76\">",
"     76",
"    </a>",
"    ]. In particular, 80 percent of the dermatologists would reexcise nevi with moderate atypia and positive margins, 95 percent would reexcise nevi with severe atypia and positive margins, and 67 percent would reexcise nevi with severe atypia even if margins were clear.",
"   </p>",
"   <p>",
"    The evidence to support reexcision rather than observation of atypical nevi histologic atypia and margin involvement is limited. In a small study of 55 atypical nevi (26 with positive margins) that were not reexcised, no melanomas or recurrent nevi developed during a follow-up of at least five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/77\">",
"     77",
"    </a>",
"    ]. In another study of 195 biopsied atypical nevi with mild (179) or moderate (16) atypia, clinical recurrence was observed at seven biopsy sites (4 percent) after &ge;2 years of follow-up. All seven recurrent nevi had been biopsied by shave biopsy and five of them had positive margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417714\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education on the importance of skin self-examination and sun protection is an integral part of the management of patients with atypical nevi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14455012\">",
"    <span class=\"h3\">",
"     Skin self-examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular skin self-examination is recommended for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melanomas are first detected by patients in about half of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-examination, particularly when combined with regular clinician examination, may be associated with early diagnosis of melanoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-examination may reduce melanoma incidence and the risk of advanced disease among melanoma patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient information on how to perform self-examination and recognize early signs of melanoma is available from several organizations including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Dermatology (",
"      <a class=\"external\" href=\"file://www.aad.org/spot-skin-cancer/understanding-skin-cancer/how-do-i-check-my-skin/how-to-perform-a-self-exam\">",
"       www.aad.org/spot-skin-cancer/understanding-skin-cancer/how-do-i-check-my-skin/how-to-perform-a-self-exam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Skin Cancer Foundation (",
"      <a class=\"external\" href=\"file://www.skincancer.org/skin-cancer-information/early-detection\">",
"       www.skincancer.org/skin-cancer-information/early-detection",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The American Cancer Society (",
"      <a class=\"external\" href=\"file://www.cancer.org/cancer/skincancer-melanoma/index\">",
"       www.cancer.org/cancer/skincancer-melanoma/index",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      GenoMEL - The Melanoma Genetics Consortium (",
"      <a class=\"external\" href=\"file://www.genomel.org/patient_information.php\">",
"       www.genomel.org/patient_information.php",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Educating patients to identify clinical outliers (&ldquo;ugly ducklings&rdquo;) may also be beneficial. In an interobserver agreement study involving dermatologists, nurses, and nonclinicians, the sensitivity and specificity of the ugly duckling sign in the detection of melanoma were 0.85 and 0.83, respectively, among nonclinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14455026\">",
"    <span class=\"h3\">",
"     Sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun avoidance and use of protective clothing, sunglasses, and broad-spectrum sunscreens are recommended for individuals with atypical nevi (",
"    <a class=\"graphic graphic_table graphicRef83780 \" href=\"mobipreview.htm?17/0/17419\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary prevention of melanoma\", section on 'Sun protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial in the general population, regular application of sunscreen with sun protection factor (SPF) &gt;15 for a four-year period reduced the incidence of primary melanomas in the following 10 years by 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/83\">",
"     83",
"    </a>",
"    ]. In a three-year randomized trial, children who used a SPF 30 broad-spectrum sunscreen developed fewer nevi than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tanning bed (or sun lamp) use is associated with an increased risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. Patients with atypical nevi, especially young patients and those with numerous atypical nevi or family history of melanoma should be advised to avoid indoor tanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14455033\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling is not indicated for patients with atypical nevi in the absence of a family history suggesting the FAMMM syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Germline mutations in CDKN2A have been found in 20 to 40 percent of families in which three or more first-degree relatives had melanoma, although penetrance varies with sun exposure and birth cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/14\">",
"     14",
"    </a>",
"    ]. The Melanoma Genetics Consortium recommends that DNA testing for mutations in melanoma susceptibility genes be performed only rarely outside of defined research programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=see_link&amp;anchor=H19#H19\">",
"     \"Inherited susceptibility to melanoma\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417634\">",
"    <span class=\"h2\">",
"     Ophthalmologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine ophthalmologic examination is indicated in patients with many atypical nevi because they have an increased prevalence of ocular melanocytic nevi and may be at increased risk of developing ocular melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8122?source=see_link&amp;anchor=H4#H4\">",
"     \"Ocular melanoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238019\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal frequency of skin examinations in individuals with atypical nevi has not been determined. Examinations are generally performed at intervals of 3 to 12 months, based upon phenotypic characteristics, personal or family history of melanoma, and competence in self examination. High risk patients should be ideally followed in a pigmented lesion clinic or by a clinician with experience in the diagnosis of melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238034\">",
"    <span class=\"h3\">",
"     Patients with few common nevi and one or few atypical nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest annual total body skin examination for patients with few common nevi and one or few atypical nevi without a personal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history of melanoma. The frequency of skin examination may be higher for patients who have a personal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history of melanoma or lower if the patient is proficient at self skin examination.",
"   </p>",
"   <p>",
"    Baseline digital photographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermoscopic images of single atypical nevi may be useful for comparison at follow-up visits. (See",
"    <a class=\"local\" href=\"#H14454991\">",
"     'Total body photography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14454998\">",
"     'Dermoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H416502\">",
"    <span class=\"h3\">",
"     Patients with numerous common and atypical nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with numerous atypical and common nevi have a high risk of developing melanoma. The risk is greatest for patients who also have a personal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history of melanoma and for patients with the FAMMM syndrome. These high risk patients should be ideally followed in a pigmented lesion clinic or by a clinician with experience in the diagnosis of melanoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with many atypical nevi without personal or family history of melanoma, we suggest total body skin examinations at six-month intervals or earlier if the patient notices any changes in a lesion size, shape, or color. Follow-up may be annually for patients who are judged competent at self-surveillance.",
"     </li>",
"     <li>",
"      For patients who have a personal history of melanoma, we suggest follow-up visits at three- to six-month intervals or earlier if the patient notices any changes in a lesion size, shape, or color.",
"     </li>",
"     <li>",
"      In FAMMM kindreds, screening for melanoma should begin around puberty with a baseline total body skin examination. Follow-up examinations are scheduled every six months until the nevus pattern is stable and the patient is judged competent at self-surveillance, and then annually [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/35,89,95\">",
"       35,89,95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk patients should be advised to perform monthly skin self-examinations. Ideally, a family member or partner should be involved in the examination of areas not accessible to self-examination. (See",
"    <a class=\"local\" href=\"#H14455012\">",
"     'Skin self-examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Total body photography and digital dermoscopy may be particularly useful in the management of patients with high mole counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/36/41545/abstract/16,17,59-62\">",
"     16,17,59-62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14454991\">",
"     'Total body photography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14454998\">",
"     'Dermoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14455047\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical (dysplastic) nevi are benign acquired melanocytic neoplasms that share some of the clinical features of melanoma, such as large diameter, irregular borders, and multiple colors (",
"      <a class=\"graphic graphic_picture graphicRef83351 \" href=\"mobipreview.htm?7/50/7972\">",
"       picture 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14454900\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with atypical nevi have a 3- to 20-fold higher risk of developing a melanoma than individuals without atypical nevi. The risk of melanoma increases in a dose-response fashion with the number of atypical nevi and is greatest in individuals with atypical nevi and a personal or family history of melanoma. (See",
"      <a class=\"local\" href=\"#H416834\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical nevi are most often seen on the trunk and extremities, although they can develop anywhere on the body, including the scalp, breasts, buttocks, and genitalia (",
"      <a class=\"graphic graphic_picture graphicRef78891 graphicRef83351 \" href=\"mobipreview.htm?21/57/22425\">",
"       picture 1A, 2A",
"      </a>",
"      ). Clinical features include diameter &gt;5 mm (",
"      <a class=\"graphic graphic_picture graphicRef80725 \" href=\"mobipreview.htm?7/52/8006\">",
"       picture 1B",
"      </a>",
"      ), prominent macular component (",
"      <a class=\"graphic graphic_picture graphicRef83466 \" href=\"mobipreview.htm?20/35/21042\">",
"       picture 3",
"      </a>",
"      ), irregular, ill-defined borders (",
"      <a class=\"graphic graphic_picture graphicRef70320 \" href=\"mobipreview.htm?13/49/14099\">",
"       picture 1C",
"      </a>",
"      ), and variegated color (",
"      <a class=\"graphic graphic_picture graphicRef83351 \" href=\"mobipreview.htm?7/50/7972\">",
"       picture 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1008077\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, atypical nevi are characterized by architectural disorder, cytologic atypia, and host response features. (See",
"      <a class=\"local\" href=\"#H14454956\">",
"       'Histologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of atypical nevus is usually clinical, based upon the finding of a predominantly macular pigmented lesion that is &gt;5 mm with irregular shape, ill-defined borders, and variable color (",
"      <a class=\"graphic graphic_picture graphicRef83351 graphicRef80725 graphicRef70320 \" href=\"mobipreview.htm?29/5/29786\">",
"       picture 1A-C",
"      </a>",
"      ). Biopsy is not indicated to confirm the presence of histologic dysplasia.",
"     </li>",
"     <li>",
"      The management of patients with atypical nevi may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment of history (see",
"      <a class=\"local\" href=\"#H962027\">",
"       'History'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Total body skin examination (see",
"      <a class=\"local\" href=\"#H14454984\">",
"       'Skin examination'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Use of diagnostic aids such as dermoscopy and total body photography (see",
"      <a class=\"local\" href=\"#H14454991\">",
"       'Total body photography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14454998\">",
"       'Dermoscopy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Excision and histologic examination of suspicious lesions (see",
"      <a class=\"local\" href=\"#H647927\">",
"       'Biopsy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Education on skin self-examination and sun protection (see",
"      <a class=\"local\" href=\"#H14455012\">",
"       'Skin self-examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14455026\">",
"       'Sun protection'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Genetic counseling (see",
"      <a class=\"local\" href=\"#H14455033\">",
"       'Genetic counseling'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lifelong follow-up (see",
"      <a class=\"local\" href=\"#H238019\">",
"       'Follow-up'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal frequency of skin examinations in individuals with atypical nevi has not been determined. We suggest annual total body skin examinations for patients with few common nevi and one or a few atypical nevi without personal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family history of melanoma. The frequency of skin examination may be higher (every 6 to 12 months) for patients who have a personal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family history of melanoma. (See",
"      <a class=\"local\" href=\"#H238034\">",
"       'Patients with few common nevi and one or few atypical nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with many atypical nevi without personal or family history of melanoma, we suggest total body skin examinations at six-month intervals or earlier if the patient notices any changes in a lesion size, shape, or color. For patients who have a personal history of melanoma, we suggest follow-up visits at three- to six-month intervals or earlier if the patient notices any changes in a lesion size, shape, or color. In FAMMM kindreds, screening for melanoma should begin at the age of 10. (See",
"      <a class=\"local\" href=\"#H416502\">",
"       'Patients with numerous common and atypical nevi'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/1\">",
"      Elder DE. Dysplastic naevi: an update. Histopathology 2010; 56:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/2\">",
"      Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/3\">",
"      Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/4\">",
"      Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978; 239:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/5\">",
"      Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/6\">",
"      Greene MH, Clark WH Jr, Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980; 2:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/7\">",
"      Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. J Am Acad Dermatol 1990; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnosis and Treatment of Early Melanoma. NIH Consens Statement Online 1992 Jan 27-29;10(1):1-26. file://consensus.nih.gov/1992/1992Melanoma088html.htm (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/9\">",
"      Piepkorn M, Meyer LJ, Goldgar D, et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989; 20:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/10\">",
"      Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/11\">",
"      Sch&auml;fer T, Merkl J, Klemm E, et al. The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000. J Invest Dermatol 2006; 126:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/12\">",
"      Augustsson A, Stierner U, Suurk&uuml;la M, Rosdahl I. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991; 124:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/13\">",
"      Halpern AC, Guerry D 4th, Elder DE, et al. Natural history of dysplastic nevi. J Am Acad Dermatol 1993; 29:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/14\">",
"      Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/15\">",
"      Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/16\">",
"      Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991; 17:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/17\">",
"      Halpern AC, Guerry D 4th, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100:346S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/18\">",
"      Garbe C, Kr&uuml;ger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989; 28:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/19\">",
"      Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/20\">",
"      Augustsson A, Stierner U, Rosdahl I, Suurk&uuml;la M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991; 71:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/21\">",
"      Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/22\">",
"      Kang S, Barnhill RL, Mihm MC Jr, et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/23\">",
"      Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/24\">",
"      Chang YM, Newton-Bishop JA, Bishop DT, et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009; 124:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/25\">",
"      Abadir MC, Marghoob AA, Slade J, et al. Case-control study of melanocytic nevi on the buttocks in atypical mole syndrome: role of solar radiation in the pathogenesis of atypical moles. J Am Acad Dermatol 1995; 33:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/26\">",
"      Kopf AW, Lindsay AC, Rogers GS, et al. Relationship of nevocytic nevi to sun exposure in dysplastic nevus syndrome. J Am Acad Dermatol 1985; 12:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/27\">",
"      Augustsson A, Stierner U, Rosdahl I, Suurk&uuml;la M. Melanocytic naevi in sun-exposed and protected skin in melanoma patients and controls. Acta Derm Venereol 1991; 71:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/28\">",
"      Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/29\">",
"      Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/30\">",
"      Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 2007; 29:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/31\">",
"      Sini MC, Manca A, Cossu A, et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 2008; 158:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/32\">",
"      Uribe P, Wistuba II, Gonz&aacute;lez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003; 25:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/33\">",
"      Celebi JT, Ward KM, Wanner M, et al. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol 2005; 30:68.",
"     </a>",
"    </li>",
"    <li>",
"     Eckerle Mize D, Bishop M, Resse E, Sluzevich J. Familial Atypical Multiple Mole Melanoma Syndrome. In: Cancer Syndromes [Internet], Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M.  (Eds), National Center for Biotechnology Information (US), Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     Eckerle Mize D, Bishop M, Resse E, et al. Familial Atypical Multiple Mole Melanoma Syndrome. In: Cancer Syndromes [Internet], Riegert-Johnson DL, Boardman LA, Hefferon T, et al (Eds), National Center for Biotechnology Information (US), Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/36\">",
"      Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/37\">",
"      Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/38\">",
"      Gupta M, Berk DR, Gray C, et al. Morphologic features and natural history of scalp nevi in children. Arch Dermatol 2010; 146:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/39\">",
"      Aguilera P, Puig S, Guilabert A, et al. Prevalence study of nevi in children from Barcelona. Dermoscopy, constitutional and environmental factors. Dermatology 2009; 218:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/40\">",
"      Synnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Frequency and distribution pattern of melanocytic naevi in Swedish 8-9-year-old children. Acta Derm Venereol 2004; 84:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/41\">",
"      Tucker MA, Fraser MC, Goldstein AM, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 2002; 94:3192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/42\">",
"      Bevona C, Goggins W, Quinn T, et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/43\">",
"      Marks R, Dorevitch AP, Mason G. Do all melanomas come from \"moles\"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/44\">",
"      Crutcher WA, Cohen PJ. Dysplastic nevi and malignant melanoma. Am Fam Physician 1990; 42:372.",
"     </a>",
"    </li>",
"    <li>",
"     Robinson JK. Surgery of the Skin: Procedural Dermatology - Expert Consult, 2nd ed, Mosby, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/46\">",
"      Bolognia JL, Lin A, Shapiro PE. The significance of eccentric foci of hyperpigmentation ('small dark dots') within melanocytic nevi. Analysis of 59 cases. Arch Dermatol 1994; 130:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/47\">",
"      Scope A, Burroni M, Agero AL, et al. Predominant dermoscopic patterns observed among nevi. J Cutan Med Surg 2006; 10:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/48\">",
"      Suh KY, Bolognia JL. Signature nevi. J Am Acad Dermatol 2009; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/49\">",
"      Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/50\">",
"      Scope A, Dusza SW, Halpern AC, et al. The \"ugly duckling\" sign: agreement between observers. Arch Dermatol 2008; 144:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/51\">",
"      Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol 2001; 137:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/52\">",
"      Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2002; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/53\">",
"      Annessi G, Cattaruzza MS, Abeni D, et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. J Am Acad Dermatol 2001; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/54\">",
"      de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993; 29A:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/55\">",
"      Duncan LM, Berwick M, Bruijn JA, et al. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993; 100:318S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/56\">",
"      Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994; 30:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/57\">",
"      Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003; 16:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/58\">",
"      Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986; 14:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/59\">",
"      Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997; 167:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/60\">",
"      Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004; 150:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/61\">",
"      Wang SQ, Kopf AW, Koenig K, et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol 2004; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/62\">",
"      Risser J, Pressley Z, Veledar E, et al. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol 2007; 57:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/63\">",
"      Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/64\">",
"      Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/65\">",
"      Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/66\">",
"      Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol 2006; 126:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/67\">",
"      Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 2000; 43:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/68\">",
"      Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol 2008; 144:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/69\">",
"      Fuller SR, Bowen GM, Tanner B, et al. Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg 2007; 33:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/70\">",
"      Menzies SW, Gutenev A, Avramidis M, et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001; 137:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/71\">",
"      National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol 1993; 15:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/72\">",
"      Park HK, Leonard DD, Arrington JH 3rd, Lund HZ. Recurrent melanocytic nevi: clinical and histologic review of 175 cases. J Am Acad Dermatol 1987; 17:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/73\">",
"      Kornberg R, Ackerman AB. Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. Arch Dermatol 1975; 111:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/74\">",
"      Sommer LL, Barcia SM, Clarke LE, Helm KF. Persistent melanocytic nevi: a review and analysis of 205 cases. J Cutan Pathol 2011; 38:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/75\">",
"      Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol 2002; 46:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/76\">",
"      Duffy KL, Mann DJ, Petronic-Rosic V, Shea CR. Clinical decision making based on histopathologic grading and margin status of dysplastic nevi. Arch Dermatol 2012; 148:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/77\">",
"      Kmetz EC, Sanders H, Fisher G, et al. The role of observation in the management of atypical nevi. South Med J 2009; 102:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/78\">",
"      Goodson AG, Florell SR, Boucher KM, Grossman D. Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol 2010; 62:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/79\">",
"      Fisher NM, Schaffer JV, Berwick M, Bolognia JL. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005; 53:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/80\">",
"      Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with thorough skin self-examination: the \"Check It Out\" randomized trial. Am J Prev Med 2007; 32:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/81\">",
"      Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/82\">",
"      Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/83\">",
"      Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/84\">",
"      Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000; 283:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/85\">",
"      Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer 2011; 128:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/86\">",
"      International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/87\">",
"      Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 19:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/88\">",
"      Veier&oslash;d MB, Adami HO, Lund E, et al. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010; 19:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/89\">",
"      Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/90\">",
"      Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61:677.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/91\">",
"      Toth-Molnar E, Olah J, Dobozy A, Hammer H. Ocular pigmented findings in patients with dysplastic naevus syndrome. Melanoma Res 2004; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/92\">",
"      Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology 2009; 116:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/93\">",
"      Rodriguez-Sains RS. Ocular findings in patients with dysplastic nevus syndrome. An update. Dermatol Clin 1991; 9:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/94\">",
"      Hammer H, Ol&aacute;h J, T&oacute;th-Moln&aacute;r E. Dysplastic nevi are a risk factor for uveal melanoma. Eur J Ophthalmol 1996; 6:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/36/41545/abstract/95\">",
"      Czajkowski R, Placek W, Drewa G, et al. FAMMM syndrome: pathogenesis and management. Dermatol Surg 2004; 30:291.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13519 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41545=[""].join("\n");
var outline_f40_36_41545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14455047\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454900\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1007470\">",
"      TERMINOLOGY AND HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454921\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H416834\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454935\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H237810\">",
"      FAMMM syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454942\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1008077\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H960751\">",
"      The \"signature nevus\" and \"ugly duckling\" sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37327243\">",
"      DERMOSCOPIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454956\">",
"      HISTOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H237624\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55979238\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14454977\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H962027\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14454984\">",
"      Skin examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14454991\">",
"      Total body photography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14454998\">",
"      Dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14455005\">",
"      - Short-term monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647927\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H647934\">",
"      - Reexcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H417714\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14455012\">",
"      - Skin self-examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14455026\">",
"      - Sun protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14455033\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H417634\">",
"      Ophthalmologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H238019\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H238034\">",
"      - Patients with few common nevi and one or few atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H416502\">",
"      - Patients with numerous common and atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14455047\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13519|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/30/41449\" title=\"figure 1\">",
"      Benign patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13519|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/50/7972\" title=\"picture 1A\">",
"      Atypical nevus 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/52/8006\" title=\"picture 1B\">",
"      Atypical nevi size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/49/14099\" title=\"picture 1C\">",
"      Atypical nevi borders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/62/30693\" title=\"picture 2A\">",
"      Multiple atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/22/12645\" title=\"picture 2B\">",
"      Eclipse nevus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/35/21042\" title=\"picture 3\">",
"      Atypical nevus - fried egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/31/43507\" title=\"picture 4A\">",
"      Melanoma in atypical nevus 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/33/14868\" title=\"picture 4B\">",
"      Melanoma in atypical nevus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/34/26144\" title=\"picture 5\">",
"      Nevus diffuse reticular pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/1/15377\" title=\"picture 6\">",
"      Nevus patchy reticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/1/30737\" title=\"picture 7\">",
"      Nevus central hypopigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/22/15714\" title=\"picture 8\">",
"      Nevus central hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/30/20962\" title=\"picture 9\">",
"      Nevus homogeneous pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/27/8626\" title=\"picture 10\">",
"      Nevus central globular pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/28/42434\" title=\"picture 11\">",
"      Nevus peripheral globules starburst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/45/16080\" title=\"picture 12\">",
"      Nevus globular pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/58/30639\" title=\"picture 13\">",
"      Nevus with a two-component pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/52/12096\" title=\"picture 14\">",
"      Nevus multi-component pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/3/37939\" title=\"picture 15A\">",
"      Superficial spreading melanoma 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/53/850\" title=\"picture 15B\">",
"      Superficial spreading melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/28/17860\" title=\"picture 15C\">",
"      Superficial spreading melanoma 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/61/18389\" title=\"picture 15D\">",
"      Melanoma- superficial spreading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/52/42817\" title=\"picture 16A\">",
"      Compound nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/55/19313\" title=\"picture 16B\">",
"      Junctional nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/46/33506\" title=\"picture 17A\">",
"      Small congenital nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35392\" title=\"picture 17B\">",
"      Small CMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/58/32676\" title=\"picture 18\">",
"      Pigmented basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/4/25668\" title=\"picture 19A\">",
"      Seborrheic keratosis irregular pigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/60/963\" title=\"picture 19B\">",
"      Seborrheic keratosis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/3/23606\" title=\"picture 19C\">",
"      Seborrehic keratosis - pigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/1/39954\" title=\"picture 20\">",
"      Numerous atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/39/20092\" title=\"table 1\">",
"      Atypical mole syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/26/42411\" title=\"table 2\">",
"      Clinical features of nevi and melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/0/17419\" title=\"table 3\">",
"      Sun protection measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7447?source=related_link\">",
"      Congenital melanocytic nevi and speckled lentiginous nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8122?source=related_link\">",
"      Ocular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_36_41546="Old anterior MI tutorial";
var content_f40_36_41546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1267px;\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Chronic anterior wall myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chronic anterior wall infarction is diagnosed by the presence of initial deep and broad Q waves in any of the precordial leads; in this case they are present in leads V1 to V4.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41546=[""].join("\n");
var outline_f40_36_41546=null;
var title_f40_36_41547="Chemical and physical agents that are reproductive hazards";
var content_f40_36_41547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemical and physical agents that are reproductive hazards for women in the workplace",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Observed effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potentially exposed workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer treatment drugs (eg., methotrexate)",
"       </td>",
"       <td>",
"        Infertility, miscarriage, birth defects, low birth weight",
"       </td>",
"       <td>",
"        Health care workers, pharmacists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Certain ethylene glycol ethers such as:",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Miscarriage",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Electronic and semiconductor workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-ethoxyethanol (2EE) and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2-methoxyethanol (2ME)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon disulfide (CS2)",
"       </td>",
"       <td>",
"        Menstrual cycle changes",
"       </td>",
"       <td>",
"        Viscose rayon workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead",
"       </td>",
"       <td>",
"        Infertility, miscarriage, low birth weight, developmental disorders",
"       </td>",
"       <td>",
"        Battery makers, solderers, welders, radiator repairers, bridge repainters, firing range workers, home remodelers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ionizing radiation (eg., X-rays and gamma rays)",
"       </td>",
"       <td>",
"        Infertility, miscarriage, birth defects, low birth weight, developmental disorders, childhood cancers",
"       </td>",
"       <td>",
"        Health care workers, dental personnel, atomic workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strenuous physical labor (eg., prolonged standing, heavy lifting)",
"       </td>",
"       <td>",
"        Miscarriage, premature delivery",
"       </td>",
"       <td>",
"        Many types of workers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     National Institute for Occupational Safety and Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41547=[""].join("\n");
var outline_f40_36_41547=null;
var title_f40_36_41548="Properties of hyaluronic acid fillers";
var content_f40_36_41548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of hyaluronic acid fillers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hylaform",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hylaform Plus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevelle Silk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Restylane",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perlane",
"       </td>",
"       <td class=\"subtitle1\">",
"        Juvederm Ultra*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Juvederm Ultra Plus*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elevess",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total HA concentration (mg/mL)",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent cross-linked HA",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel/fluid ratio",
"       </td>",
"       <td>",
"        98/2",
"       </td>",
"       <td>",
"        98/2",
"       </td>",
"       <td>",
"        98/2",
"       </td>",
"       <td>",
"        75/25",
"       </td>",
"       <td>",
"        75/25",
"       </td>",
"       <td>",
"        90/10",
"       </td>",
"       <td>",
"        90/10",
"       </td>",
"       <td>",
"        100/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HA gel concentration (mg/mL)",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        17.3",
"       </td>",
"       <td>",
"        17.3",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         G&prime;",
"        </em>",
"        modulus (Pa)",
"       </td>",
"       <td>",
"        140-220",
"       </td>",
"       <td>",
"        140-220",
"       </td>",
"       <td>",
"        230-260",
"       </td>",
"       <td>",
"        660",
"       </td>",
"       <td>",
"        588",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        329",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average particulate size (&micro;m)",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        350",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        650",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anesthetic included",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N/A: data not available.",
"     <br>",
"      * Data provided by Allergan.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Data provided by Anika Therapeutics.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: A comprehensive review. Facial Plast Surg 2009; 25:86. Copyright &copy; 2009 Thieme Medical Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41548=[""].join("\n");
var outline_f40_36_41548=null;
var title_f40_36_41549="Causes of chronic wrist injury in children and adolescents";
var content_f40_36_41549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic wrist injury in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal radius physis stress syndrome",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Pain with dorsiflexion and axial loading",
"       </td>",
"       <td>",
"        Widening and irregularity of the physis; palmar spurring of metaphysis",
"       </td>",
"       <td>",
"        Gymnastics; rock climbing; weight lifting;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median neuropathy (Carpal tunnel syndrome)",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Dysesthesia or paresthesias; positive Tinels or Phelan sign",
"       </td>",
"       <td>",
"        Carpal tunnel view to exclude osseous compression",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports; cycling; rowing; skiing; keyboard typing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radial neuropathy (Wartenburg syndrome)",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Pain and paresthesias over the dorsal thumb and dorsal radial hand",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Activities that involve repeated supination and pronation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scaphoid impaction",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Pain over the scapholunate ligament when wrist is dorsiflexed and axially loaded",
"       </td>",
"       <td>",
"        Normal or may demonstrate ossicle formation",
"       </td>",
"       <td>",
"        Gymnastics; weight lifting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        de Quervain tenosynovitis",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Pain during pinch grasping or thumb and wrist movement",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports; fly fishing; repetitive thumb extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal ganglion",
"       </td>",
"       <td>",
"        Radial, dorsal",
"       </td>",
"       <td>",
"        Cystic swelling",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kienbock disease(Osteonecrosis of the lunate)",
"       </td>",
"       <td>",
"        Radial, dorsal",
"       </td>",
"       <td>",
"        Mild swelling, persistent pain, crepitation, stiffness and decreased range of motion",
"       </td>",
"       <td>",
"        AP radiographs demonstrate progressive changes",
"       </td>",
"       <td>",
"        Martial arts; volleyball",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulnar neuropathy (Guyon canal syndrome)",
"       </td>",
"       <td>",
"        Ulnar",
"       </td>",
"       <td>",
"        Weakness and paresthesias affecting the 4th and 5th digits",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports, cycling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulnar impaction syndrome",
"       </td>",
"       <td>",
"        Ulnar",
"       </td>",
"       <td>",
"        Tenderness of ulnar snuff box; tenderness with ulnar deviation",
"       </td>",
"       <td>",
"        Positive ulnar variance, cyst formation or sclerosis of ulnar head or lunotriquetral interface",
"       </td>",
"       <td>",
"        Gymnastics (vaulting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triangular fibrocartilage complex (TFCC) tears",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Point tenderness over the lateral wrist just distal to the ulnar styloid; pain with forced ulnar deviation or TFCC compression test",
"       </td>",
"       <td>",
"        Associated (but not diagnostic) findings: widening of DRUJ space, positive ulnar variance, fracture of ulnar styloid on AP; dislocation/subluxation on lateral",
"       </td>",
"       <td>",
"        Impact sports; racquet, stick, and club sports; gymnastics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal radioulnar joint (DRUJ) injury",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Pain with supination and pronation; positive DRUJ compression or piano key tests",
"       </td>",
"       <td>",
"        Dislocation can be seen on plain radiographs; MRI may be necessary for instability",
"       </td>",
"       <td>",
"        Impact sports; racquet, stick, and club sports; gymnastics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensor carpi ulnaris (ECU) tendonitis",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Tenderness over ECU tendon in ulnar groove exacerbated by wrist extension against resistance",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Rowing; racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ECU subluxation",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Pain and snapping with rotation of forearm; can be observed with ulnar deviation in full supination",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hamate hook fracture",
"       </td>",
"       <td>",
"        Ulnar, palmar",
"       </td>",
"       <td>",
"        Pain with sports but not daily activities; point tenderness over the hook of the hamate",
"       </td>",
"       <td>",
"        Fracture best seen on 45&deg; supination oblique or carpal tunnel view or with computed tomography",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexor tendonitis (flexor carpi radialis [FCR], fexor carpi ulnaris [FCU])",
"       </td>",
"       <td>",
"        Palmar",
"       </td>",
"       <td>",
"        Tenderness over FCR or FCU",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothenar hammer syndrome",
"       </td>",
"       <td>",
"        Palmar",
"       </td>",
"       <td>",
"        Pain in palm, coldness of digits, abnormal modified Allen test",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Impact sports; martial arts; volleyball; racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intersection syndrome",
"       </td>",
"       <td>",
"        Dorsal",
"       </td>",
"       <td>",
"        Tenderness 4 to 6 cm proximal to wrist joint; crepitus with active extension of the wrist",
"       </td>",
"       <td>",
"        Radiographs not necessary",
"       </td>",
"       <td>",
"        Rowing; weight training; racquet, stick, and club sports",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41549=[""].join("\n");
var outline_f40_36_41549=null;
var title_f40_36_41550="Obstruction post HS";
var content_f40_36_41550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis and management of the child with obstructive symptoms after a pull-through operation for Hirschsprung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 498px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Botox: Botulinum toxin injection in the anal sphincter",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Langer, JC. Persistent obstructive symptoms after surgery for Hirschsprung's Disease: Development of a diagnostic and therapeutic algorithm. J Pediatr Surg 2004; 39:1458. Copyright &copy;2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41550=[""].join("\n");
var outline_f40_36_41550=null;
var title_f40_36_41551="Filiform polyps in UC BE";
var content_f40_36_41551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Filiform polyps in chronic ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema shows fine linear polyps arising from the colon wall (arrows). These polyps are typically seen in chronic ulcerative colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_36_41551=[""].join("\n");
var outline_f40_36_41551=null;
